The	O
immediate-early	O
gene	O
product	O
Egr-1	B-protein
regulates	O
the	O
human	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
beta-chain	I-DNA
promoter	I-DNA
through	O
noncanonical	B-DNA
Egr	I-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

The	O
interleukin-2	B-protein
IL-2	I-protein
receptor	I-protein
beta-chain	I-protein
(	O
IL-2Rbeta	B-protein
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL-2	B-protein
and	O
IL-15	B-protein
.	O

Although	O
IL-2Rbeta	B-protein
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	B-DNA
-170	I-DNA
and	I-DNA
-139	I-DNA
of	O
the	O
human	O
IL-2Rbeta	B-DNA
promoter	I-DNA
.	O

Both	O
Sp1	B-protein
and	O
Sp3	B-protein
bound	O
to	O
the	O
5	B-DNA
'	I-DNA
portion	I-DNA
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA-inducible	B-protein
factor	I-protein
(	O
PIF	B-protein
)	O
mainly	O
bound	O
to	O
its	O
3	B-DNA
'	I-DNA
portion	I-DNA
and	O
bound	O
to	O
the	O
Sp	B-DNA
binding	I-DNA
motifs	I-DNA
as	O
well	O
.	O

In	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
induction	O
of	O
PIF	B-protein
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O

Interestingly	O
,	O
PIF	B-protein
was	O
constitutively	O
activated	O
in	O
human	B-cell_line
T-cell	I-cell_line
leukemia	I-cell_line
virus	I-cell_line
type	I-cell_line
1-transformed	I-cell_line
MT-2	I-cell_line
cells	I-cell_line
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
PIF	B-protein
is	O
Egr-1	B-protein
based	O
on	O
its	O
recognition	O
by	O
anti-	O
Egr-1	B-protein
antisera	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
even	O
though	O
the	O
IL-2Rbeta	B-DNA
DNA	I-DNA
binding	I-DNA
motif	I-DNA
differed	O
substantially	O
from	O
the	O
canonical	O
Egr-1	B-DNA
binding	I-DNA
site	I-DNA
.	O

In	O
addition	O
,	O
Egr-1	B-protein
bound	O
to	O
the	O
Sp	B-DNA
binding	I-DNA
site	I-DNA
.	O

In	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL-2Rbeta	B-protein
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr-1	B-protein
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O

Moreover	O
,	O
Sp1	B-protein
and	O
Egr-1	B-protein
could	O
form	O
a	O
complex	O
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	O
of	O
Egr-1	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
upon	O
PMA	O
stimulation	O
.	O

Thus	O
,	O
Sp1	B-protein
and	O
Egr-1	B-protein
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	O
maximal	O
IL-2Rbeta	B-DNA
promoter	I-DNA
activity	O
.	O

MOLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLOGY	NULL
,	NULL
July	NULL
1997	NULL
,	NULL
p.	NULL
3714-3722	NULL
0270-7306/97/	NULL
$	NULL
04.00+0	NULL
The	NULL
Immediate-Early	NULL
Gene	NULL
Product	NULL
Egr-1	NULL
Regulates	NULL
the	NULL
Human	NULL
Interleukin-2	NULL
Receptor	NULL
B-Chain	NULL
Promoter	NULL
through	NULL
Noncanonical	NULL
Egr	NULL
and	NULL
Sp1	NULL
Binding	NULL
Sites	NULL
JIAN-XIN	NULL
LIN	NULL
anp	NULL
WARREN	NULL
J.	NULL
LEONARD*	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Immunology	NULL
,	NULL
National	NULL
Heart	NULL
,	NULL
Lung	NULL
,	NULL
and	NULL
Blood	NULL
Institute	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892-1674	NULL
Received	NULL
19	NULL
August	NULL
1996/Returned	NULL
for	NULL
modification	NULL
11	NULL
October	NULL
1996/Accepted	NULL
8	NULL
April	NULL
1997	NULL
The	NULL
interleukin-2	NULL
IL-2	NULL
receptor	NULL
B-chain	NULL
(	NULL
IL-2R	NULL
$	NULL
)	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
receptors	NULL
for	NULL
IL-2	NULL
and	NULL
IL-15	NULL
.	NULL

Although	NULL
IL-2Rf	NULL
is	NULL
constitutively	NULL
expressed	NULL
by	NULL
lymphocytes	NULL
,	NULL
its	NULL
expression	NULL
can	NULL
be	NULL
further	NULL
induced	NULL
by	NULL
a	NULL
number	NULL
of	NULL
stimuli	NULL
,	NULL
including	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
.	NULL

We	NULL
have	NULL
now	NULL
characterized	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
an	NULL
enhancer	NULL
region	NULL
located	NULL
between	NULL
nucleotides	NULL
-170	NULL
and	NULL
-139	NULL
of	NULL
the	NULL
human	NULL
IL-2RfB	NULL
promoter	NULL
.	NULL

Both	NULL
Sp1	NULL
and	NULL
Sp3	NULL
bound	NULL
to	NULL
the	NULL
5	NULL
'	NULL
portion	NULL
of	NULL
this	NULL
region	NULL
,	NULL
whereas	NULL
a	NULL
PMA-inducible	NULL
factor	NULL
(	NULL
PIF	NULL
)	NULL
mainly	NULL
bound	NULL
to	NULL
its	NULL
3	NULL
'	NULL
portion	NULL
and	NULL
bound	NULL
to	NULL
the	NULL
Sp	NULL
binding	NULL
motifs	NULL
as	NULL
well	NULL
.	NULL

In	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
induction	NULL
of	NULL
PIF	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
rapidly	NULL
induced	NULL
,	NULL
required	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
,	NULL
and	NULL
was	NULL
sustained	NULL
at	NULL
a	NULL
high	NULL
level	NULL
for	NULL
at	NULL
least	NULL
23	NULL
h.	NULL
Interestingly	NULL
,	NULL
PIF	NULL
was	NULL
constitutively	NULL
activated	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1-transformed	NULL
MT-2	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
PIF	NULL
is	NULL
Egr-1	NULL
based	NULL
on	NULL
its	NULL
recognition	NULL
by	NULL
anti-Egr-1	NULL
antisera	NULL
in	NULL
gel	NULL
mobility	NULL
shift	NULL
assays	NULL
,	NULL
even	NULL
though	NULL
the	NULL
IL-2RB	NULL
DNA	NULL
binding	NULL
motif	NULL
differed	NULL
substantially	NULL
from	NULL
the	NULL
canonical	NULL
Egr-1	NULL
binding	NULL
site	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Egr-1	NULL
bound	NULL
to	NULL
the	NULL
Sp	NULL
binding	NULL
site	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
,	NULL
both	NULL
sites	NULL
were	NULL
required	NULL
for	NULL
maximal	NULL
IL-2RfB	NULL
promoter	NULL
activity	NULL
,	NULL
and	NULL
in	NULL
HeLaS3	NULL
cells	NULL
,	NULL
transfection	NULL
of	NULL
Egr-1	NULL
could	NULL
drive	NULL
activity	NULL
of	NULL
a	NULL
reporter	NULL
construct	NULL
containing	NULL
both	NULL
sites	NULL
.	NULL

Moreover	NULL
,	NULL
Spl	NULL
and	NULL
Egr-1	NULL
could	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
kinetics	NULL
that	NULL
correlated	NULL
with	NULL
the	NULL
production	NULL
of	NULL
Egr-1	NULL
in	NULL
Jurkat	NULL
cells	NULL
upon	NULL
PMA	NULL
stimulation	NULL
.	NULL

Thus	NULL
,	NULL
Spl	NULL
and	NULL
Egr-1	NULL
physically	NULL
and	NULL
Vol	NULL
.	NULL

17	NULL
,	NULL
No	NULL
.	NULL

7	NULL
functionally	NULL
cooperate	NULL
to	NULL
mediate	NULL
maximal	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
interleukin-2	NULL
receptor	NULL
B-chain	NULL
(	NULL
IL-ZRB	NULL
)	NULL
is	NULL
a	NULL
critical	NULL
signaling	NULL
component	NULL
of	NULL
high-	NULL
and	NULL
intermediate-affinity	NULL
IL-2Rs	NULL
(	NULL
28	NULL
,	NULL
42	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Like	NULL
the	NULL
common	NULL
cytokine	NULL
y	NULL
chain	NULL
,	NULL
IL-2R	NULL
$	NULL
is	NULL
also	NULL
a	NULL
component	NULL
of	NULL
the	NULL
receptor	NULL
for	NULL
IL-15	NULL
,	NULL
a	NULL
cytokine	NULL
that	NULL
shares	NULL
a	NULL
number	NULL
of	NULL
biological	NULL
actions	NULL
with	NULL
IL-2	NULL
(	NULL
3	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Recent	NULL
evidence	NULL
derived	NULL
from	NULL
gene-targeting	NULL
experiments	NULL
has	NULL
shown	NULL
that	NULL
mice	NULL
deficient	NULL
in	NULL
IL-2RB	NULL
exhibit	NULL
dysregulated	NULL
T-cell	NULL
activation	NULL
and	NULL
autoimmunity	NULL
,	NULL
indicating	NULL
that	NULL
IL-2RB	NULL
plays	NULL
vital	NULL
roles	NULL
in	NULL
maintaining	NULL
normal	NULL
immune	NULL
responses	NULL
(	NULL
45	NULL
)	NULL
.	NULL

IL-2Rf	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
(	NULL
12	NULL
,	NULL
37	NULL
)	NULL
,	NULL
B	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
37	NULL
,	NULL
52	NULL
)	NULL
,	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
(	NULL
38	NULL
)	NULL
,	NULL
monocytes	NULL
(	NULL
14	NULL
,	NULL
37	NULL
)	NULL
,	NULL
dendritic	NULL
epidermal	NULL
cells	NULL
(	NULL
46	NULL
)	NULL
,	NULL
neutrophils	NULL
(	NULL
11	NULL
,	NULL
50	NULL
)	NULL
,	NULL
and	NULL
large	NULL
granular	NULL
lymphocyte-like	NULL
cells	NULL
in	NULL
decidua	NULL
during	NULL
early	NULL
pregnancy	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
a	NULL
number	NULL
of	NULL
stimuli	NULL
can	NULL
greatly	NULL
increase	NULL
the	NULL
levels	NULL
of	NULL
both	NULL
IL-ZRB	NULL
mRNA	NULL
and	NULL
protein	NULL
;	NULL
such	NULL
stimuli	NULL
include	NULL
the	NULL
mitogen	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
20	NULL
)	NULL
;	NULL
anti-CD3	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
,	NULL
anti-CD28	NULL
,	NULL
(	NULL
7	NULL
)	NULL
,	NULL
and	NULL
anti-CD2	NULL
plus	NULL
anti-CD28	NULL
(	NULL
7	NULL
)	NULL
antibodies	NULL
;	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
[	NULL
un-published	NULL
observations	NULL
]	NULL
)	NULL
;	NULL
IL-2	NULL
(	NULL
reference	NULL
38	NULL
and	NULL
unpublished	NULL
observations	NULL
)	NULL
;	NULL
and	NULL
IL-4	NULL
(	NULL
6	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
molecular	NULL
mechanisms	NULL
by	NULL
which	NULL
the	NULL
IL-2RB	NULL
gene	NULL
expression	NULL
is	NULL
regulated	NULL
are	NULL
not	NULL
well	NULL
understood	NULL
.	NULL

We	NULL
previously	NULL
delineated	NULL
the	NULL
regions	NULL
critical	NULL
for	NULL
basal	NULL
and	NULL
PMA-inducible	NULL
activities	NULL
of	NULL
the	NULL
human	NULL
IL-2RB	NULL
promoter	NULL
and	NULL
identified	NULL
three	NULL
enhancer-like	NULL
regions	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
the	NULL
-56	NULL
to	NULL
-34	NULL
and	NULL
-170	NULL
to	NULL
-139	NULL
enhancer	NULL
regions	NULL
were	NULL
active	NULL
in	NULL
T-cell	NULL
lines	NULL
but	NULL
not	NULL
in	NULL
nonlymphoid	NULL
HeLaS3	NULL
or	NULL
MG63	NULL
cells	NULL
,	NULL
correlating	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
IL-ZRB	NULL
promoter	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

The	NULL
-56	NULL
to	NULL
-34	NULL
enhancer	NULL
contains	NULL
an	NULL
Ets	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Immunology	NULL
,	NULL
National	NULL
Heart	NULL
,	NULL
Lung	NULL
,	NULL
and	NULL
Blood	NULL
Institute	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
9000	NULL
Rockville	NULL
Pike	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892-1674	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
301	NULL
)	NULL
496-0098	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
301	NULL
)	NULL
402-0971	NULL
.	NULL

E-mail	NULL
:	NULL
wil	NULL
@	NULL
helix.nih.gov	NULL
.	NULL

3714	NULL
binding	NULL
site	NULL
(	NULL
EBS	NULL
)	NULL
that	NULL
binds	NULL
two	NULL
Ets	NULL
family	NULL
proteins	NULL
,	NULL
Ets-1	NULL
and	NULL
GA-binding	NULL
protein	NULL
(	NULL
GABP	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
integrity	NULL
of	NULL
this	NULL
site	NULL
is	NULL
critical	NULL
for	NULL
both	NULL
enhancer	NULL
and	NULL
promoter	NULL
activities	NULL
(	NULL
30	NULL
)	NULL
,	NULL
the	NULL
EBS	NULL
in	NULL
the	NULL
-56	NULL
to	NULL
-34	NULL
region	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
IL-Z2RB	NULL
promoter	NULL
activity	NULL
,	NULL
since	NULL
a	NULL
5'-deletion	NULL
reporter	NULL
construct	NULL
containing	NULL
nucleotides	NULL
-61	NULL
to	NULL
+97	NULL
is	NULL
not	NULL
active	NULL
.	NULL

Therefore	NULL
,	NULL
like	NULL
many	NULL
other	NULL
cellular	NULL
promoters	NULL
(	NULL
31	NULL
,	NULL
48	NULL
)	NULL
,	NULL
the	NULL
IL-2RB	NULL
promoter	NULL
appears	NULL
to	NULL
be	NULL
coordinately	NULL
regulated	NULL
by	NULL
multiple	NULL
elements	NULL
.	NULL

Egr-1	NULL
(	NULL
early	NULL
growth	NULL
response	NULL
protein	NULL
1	NULL
)	NULL
cDNA	NULL
was	NULL
first	NULL
isolated	NULL
as	NULL
an	NULL
immediate-early	NULL
gene	NULL
by	NULL
differential	NULL
screening	NULL
of	NULL
cDNA	NULL
libraries	NULL
made	NULL
from	NULL
BALB/c	NULL
3T3	NULL
cells	NULL
stimulated	NULL
by	NULL
serum	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cycloheximide	NULL
(	NULL
27	NULL
,	NULL
43	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
its	NULL
induction	NULL
by	NULL
mitogens	NULL
,	NULL
Egr-1	NULL
is	NULL
induced	NULL
by	NULL
other	NULL
stimuli	NULL
,	NULL
including	NULL
signals	NULL
for	NULL
development	NULL
,	NULL
differentiation	NULL
,	NULL
tissue	NULL
or	NULL
radiation	NULL
injury	NULL
,	NULL
and	NULL
neuronal	NULL
excitation	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Egr-1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
a	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
protein	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
5'-GCG	NULL
(	NULL
C/G	NULL
)	NULL
GGGCG-3	NULL
'	NULL
motif	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Like	NULL
Sp	NULL
family	NULL
proteins	NULL
,	NULL
Egr-1	NULL
also	NULL
contains	NULL
Zn	NULL
finger	NULL
structures	NULL
(	NULL
9	NULL
,	NULL
43	NULL
)	NULL
that	NULL
are	NULL
critical	NULL
for	NULL
its	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Depending	NULL
upon	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
DNA	NULL
binding	NULL
sites	NULL
nearby	NULL
the	NULL
Egr-1	NULL
site	NULL
,	NULL
it	NULL
can	NULL
cither	NULL
positively	NULL
or	NULL
negatively	NULL
regulate	NULL
gene	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
,	NULL
because	NULL
Egr-1	NULL
contains	NULL
both	NULL
transactivation	NULL
and	NULL
repression	NULL
domains	NULL
(	NULL
16	NULL
)	NULL
.	NULL

We	NULL
have	NULL
now	NULL
characterized	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
enhancer	NULL
region	NULL
of	NULL
the	NULL
human	NULL
IL-ZRB	NULL
promoter	NULL
and	NULL
found	NULL
that	NULL
Spl	NULL
,	NULL
Sp3	NULL
,	NULL
and	NULL
Egr-1	NULL
bind	NULL
to	NULL
this	NULL
region	NULL
.	NULL

We	NULL
also	NULL
demonstrate	NULL
that	NULL
both	NULL
Sp	NULL
and	NULL
Egr-1	NULL
binding	NULL
sites	NULL
at	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
enhancer	NULL
region	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Tissue	NULL
culture	NULL
,	NULL
plasmids	NULL
,	NULL
oligonucleotides	NULL
,	NULL
and	NULL
antibodies	NULL
.	NULL

Peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBLs	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
normal	NULL
donors	NULL
by	NULL
standard	NULL
methods	NULL
.	NULL

Jurkat	NULL
E6.1	NULL
cells	NULL
(	NULL
provided	NULL
by	NULL
A.	NULL
Weiss	NULL
)	NULL
and	NULL
MT	NULL
-2	NULL
cells	NULL
(	NULL
provided	NULL
by	NULL
I.	NULL
Miyoshi	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
media	NULL
supplemented	NULL
with	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
U	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
HeLaS3	NULL
cells	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
supplemented	NULL
as	NULL
mentioned	NULL
above	NULL
.	NULL

The	NULL
pBLCAT2	NULL
and	NULL
JOCAT	NULL
reporter	NULL
vectors	NULL
and	NULL
the	NULL
construction	NULL
of	NULL
the	NULL
wild-type	NULL
pTKB-170/-139	NULL
and	NULL
JMXHB-548/+97	NULL
plasmids	NULL
were	NULL
previously	NULL
described	NULL
(	NULL
30	NULL
)	NULL
.	NULL

To	NULL
mutate	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
in	NULL
the	NULL
pTKB-170/-139	NULL
construct	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
,	NULL
both	NULL
strands	NULL
of	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
sequence	NULL
with	NULL
the	NULL
designated	NULL
mutations	NULL
were	NULL
synthesized	NULL
with	NULL
HindIII	NULL
and	NULL
BamHI	NULL
sites	NULL
,	NULL
respectively	NULL
,	NULL
at	NULL
the	NULL
5	NULL
'	NULL
ends	NULL
of	NULL
the	NULL
top	NULL
and	NULL
bottom	NULL
strands	NULL
.	NULL

After	NULL
phosphorylation	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Am-ersham-U.S.	NULL
Biochemicals	NULL
)	NULL
and	NULL
ATP	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
,	NULL
each	NULL
pair	NULL
of	NULL
oligonucleotides	NULL
was	NULL
annealed	NULL
and	NULL
cloned	NULL
between	NULL
the	NULL
HindIII	NULL
and	NULL
BamHI	NULL
sites	NULL
of	NULL
pBLCAT2	NULL
.	NULL

To	NULL
mutate	NULL
the	NULL
Sp1	NULL
site	NULL
at	NULL
-169	NULL
to	NULL
-155	NULL
,	NULL
the	NULL
Egr-1	NULL
site	NULL
at	NULL
-155	NULL
to	NULL
-143	NULL
,	NULL
or	NULL
both	NULL
sites	NULL
in	NULL
the	NULL
JIMXHB-548/+97	NULL
construct	NULL
,	NULL
the	NULL
primers	NULL
5-TGTGT	NULL
GTGTGTGCCGatCCCAGCGTAGGAGGC-3	NULL
'	NULL
,	NULL
5	NULL
``	NULL
-CCGCCCCCAGCGTAGte	NULL
tGCAGATCTTTATCTG-3	NULL
'	NULL
,	NULL
and	NULL
5-CCGatCCCAGCGTAGtetGCAGATCIT	NULL
TATCTG-3	NULL
'	NULL
(	NULL
mutated	NULL
nucleotides	NULL
are	NULL
underlined	NULL
and	NULL
in	NULL
lowercase	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
used	NULL
in	NULL
conjunction	NULL
with	NULL
the	NULL
Morph	NULL
site-specific	NULL
plasmid	NULL
DNA	NULL
mutagenesis	NULL
kit	NULL
(	NULL
5	NULL
Prime-3	NULL
Prime	NULL
,	NULL
Inc.	NULL
,	NULL
Boulder	NULL
,	NULL
Colo.	NULL
)	NULL
.	NULL

All	NULL
of	NULL
the	NULL
mutant	NULL
constructs	NULL
were	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

An	NULL
Egr-1	NULL
eukaryotic	NULL
expression	NULL
vector	NULL
,	NULL
p930	NULL
,	NULL
was	NULL
previously	NULL
described	NULL
(	NULL
16	NULL
)	NULL
and	NULL
kindly	NULL
provided	NULL
by	NULL
Vikas	NULL
P.	NULL
Sukbhatme	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
)	NULL
.	NULL

The	NULL
control	NULL
plasmid	NULL
peDNA3.1Neo	NULL
was	NULL
obtained	NULL
from	NULL
Invitrogen	NULL
(	NULL
Carlsbad	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Anti-Egr-1	NULL
antiserum	NULL
R5232	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Vikas	NULL
P.	NULL
Sukhatme	NULL
and	NULL
used	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
5	NULL
)	NULL
.	NULL

All	NULL
other	NULL
antibodies	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Transient	NULL
transfection	NULL
and	NULL
CAT	NULL
assays	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
DEAE-dextran	NULL
(	NULL
Pharmacia	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

For	NULL
IL-2RB	NULL
enhancer	NULL
and	NULL
promoter	NULL
constructs	NULL
,	NULL
5	NULL
and	NULL
10	NULL
pg	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
plasmid	NULL
DNA	NULL
purified	NULL
with	NULL
Qiagen	NULL
plasmid	NULL
purification	NULL
kits	NULL
(	NULL
Qiagen	NULL
Inc.	NULL
,	NULL
Chatsworth	NULL
,	NULL
Calif.	NULL
)	NULL
were	NULL
used	NULL
.	NULL

HeLaS3	NULL
cells	NULL
were	NULL
seeded	NULL
in	NULL
100-mm-diameter	NULL
petri	NULL
dishes	NULL
,	NULL
transfected	NULL
with	NULL
5	NULL
pg	NULL
each	NULL
of	NULL
reporter	NULL
and	NULL
effector	NULL
plasmid	NULL
DNAs	NULL
with	NULL
Lipofectamine	NULL
reagent	NULL
(	NULL
Gibco-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

,	NULL
and	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
containing	NULL
0.5	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Twenty-four	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
either	NULL
were	NULL
not	NULL
treated	NULL
(	NULL
controls	NULL
)	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
PMA	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

per	NULL
ml	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
protein	NULL
concentrations	NULL
were	NULL
determined	NULL
with	NULL
the	NULL
Protein	NULL
Assay	NULL
Reagent	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
assays	NULL
(	NULL
18	NULL
)	NULL
were	NULL
performed	NULL
with	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
extracts	NULL
.	NULL

For	NULL
enhancer	NULL
and	NULL
promoter	NULL
constructs	NULL
,	NULL
the	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
and	NULL
3	NULL
h	NULL
,	NULL
respectively	NULL
.	NULL

CAT	NULL
activities	NULL
were	NULL
quantitated	NULL
by	NULL
analyzing	NULL
the	NULL
thin-layer	NULL
chro-matography	NULL
plates	NULL
(	NULL
J.	NULL
T.	NULL
Baker	NULL
Inc.	NULL
,	NULL
Phillipsburg	NULL
,	NULL
N.J.	NULL
)	NULL
with	NULL
a	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

EMSA	NULL
and	NULL
methylation	NULL
interference	NULL
assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
for	NULL
electro-phoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
concentrations	NULL
of	NULL
nuclear	NULL
proteins	NULL
were	NULL
quantitated	NULL
with	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
reagent	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
15,000	NULL
cpm	NULL
of	NULL
*°P-labeled	NULL
probes	NULL
were	NULL
used	NULL
in	NULL
each	NULL
reaction	NULL
mixture	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
30	NULL
)	NULL
.	NULL

For	NULL
competition	NULL
assays	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
for	NULL
20	NULL
min	NULL
with	NULL
25	NULL
ng	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
as	NULL
indicated	NULL
,	NULL
radiolabeled	NULL
probe	NULL
was	NULL
added	NULL
,	NULL
and	NULL
then	NULL
the	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
another	NULL
15	NULL
min	NULL
.	NULL

For	NULL
supershift	NULL
assays	NULL
,	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
probe	NULL
,	NULL
the	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
with	NULL
2	NULL
pl	NULL
of	NULL
antibody	NULL
as	NULL
indicated	NULL
.	NULL

For	NULL
methylation	NULL
interference	NULL
assays	NULL
,	NULL
probes	NULL
*°P	NULL
end	NULL
labeled	NULL
at	NULL
either	NULL
the	NULL
top	NULL
or	NULL
bottom	NULL
strands	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Typically	NULL
,	NULL
500,000	NULL
cpm	NULL
of	NULL
probes	NULL
and	NULL
30	NULL
pg	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
in	NULL
each	NULL
binding	NULL
reaction	NULL
mixture	NULL
.	NULL

Methylation	NULL
interference	NULL
assays	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Baldwin	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Southwestern	NULL
assay	NULL
,	NULL
immunoprecipitation	NULL
,	NULL
and	NULL
western	NULL
blotting	NULL
.	NULL

For	NULL
Southwestern	NULL
assays	NULL
,	NULL
30	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
was	NULL
denatured	NULL
in	NULL
Laemmli	NULL
sample	NULL
buffer	NULL
and	NULL
separated	NULL
on	NULL
7.5	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
gels	NULL
.	NULL

After	NULL
proteins	NULL
were	NULL
transferred	NULL
onto	NULL
Immobilon-P	NULL
membranes	NULL
(	NULL
Millipore	NULL
Corporation	NULL
,	NULL
Bedford	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

,	NULL
the	NULL
blots	NULL
were	NULL
incubated	NULL
in	NULL
blocking	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
60	NULL
mM	NULL
KCI	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
[	NULL
DTT	NULL
]	NULL
,	NULL
5	NULL
%	NULL
nonfat	NULL
dry	NULL
milk	NULL
)	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h	NULL
and	NULL
then	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h	NULL
in	NULL
binding	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
60	NULL
mM	NULL
KCI	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
5	NULL
pg	NULL
of	NULL
salmon	NULL
sperm	NULL
DNA	NULL
per	NULL
m	NULL
!	NULL
)	NULL

containing	NULL
400,000	NULL
cpm	NULL
of	NULL
*°P-labeled	NULL
oligonucleotides	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
then	NULL
washed	NULL
in	NULL
washing	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
60	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
)	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
the	NULL
results	NULL
were	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

For	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
blotting	NULL
,	NULL
10	NULL
X	NULL
10°	NULL
to	NULL
20	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
cold	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
lysed	NULL
in	NULL
lysis	NULL
buffer	NULL
[	NULL
50	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
1	NULL
mM	NULL
4-	NULL
(	NULL
2-aminoeth-y	NULL
)	NULL
benzenesulfonyl	NULL
fluoride	NULL
]	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
immunocomplexes	NULL
were	NULL
precipitated	NULL
with	NULL
5	NULL
pg	NULL
of	NULL
anti-Sp1	NULL
antiserum	NULL
and	NULL
recombinant	NULL
protein	NULL
G-agarose	NULL
(	NULL
Bethesda	NULL
Research	NULL
Laboratories	NULL
,	NULL
Gaithersburg	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

,	NULL
resolved	NULL
on	NULL
8	NULL
%	NULL
poly-acrylamide	NULL
gels	NULL
(	NULL
Novex	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
,	NULL
and	NULL
blotted	NULL
onto	NULL
Immobilon-P	NULL
mem-branes	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
then	NULL
blotted	NULL
with	NULL
anti-Egr-1	NULL
or	NULL
anti-Sp1	NULL
antiserum	NULL
and	NULL
developed	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
System	NULL
;	NULL
Amersham	NULL
)	NULL
.	NULL

In	NULL
some	NULL
of	NULL
the	NULL
immunoprecipitation	NULL
experiments	NULL
,	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
anti-serum	NULL
,	NULL
lysates	NULL
were	NULL
incubated	NULL
with	NULL
or	NULL
without	NULL
ethidium	NULL
bromide	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
and	NULL
cleared	NULL
by	NULL
centrifugation	NULL
at	NULL
4°C	NULL
for	NULL
5	NULL
min	NULL
to	NULL
remove	NULL
DNA	NULL
contamination	NULL
from	NULL
the	NULL
total	NULL
cell	NULL
lysate	NULL
(	NULL
26	NULL
)	NULL
.	NULL

REGULATION	NULL
OF	NULL
IL-Z2RB	NULL
PROMOTER	NULL
BY	NULL
Egr1	NULL
-	NULL
3715	NULL
A	NULL
B	NULL
Probes	NULL
:	NULL
-170/-139	NULL
m	NULL
--	NULL
--	NULL
-	NULL
Chg	NULL
:	NULL
&	NULL
Jurkat	NULL
Hela	NULL
QEQ	NULL
o	NULL
G	NULL
Competitors	NULL
:	NULL
90	NULL
‘	NULL
on	NULL
9,6	NULL
’	NULL
\°'\	NULL
6	NULL
?	NULL
)	NULL

sN	NULL
PMA	NULL
:	NULL
=	NULL
++++++	NULL
C1	NULL
-t	NULL
LBL	NULL
C2	NULL
»	NULL
C4	NULL
+	NULL
C5	NULL
-	NULL
»	NULL
mum	NULL
.	NULL

<	NULL
+	NULL
C2	NULL
C3	NULL
»	NULL
-	NULL
bub	NULL
W	NULL
tat	NULL
in	NULL
ho	NULL
n	NULL
``	NULL
«	NULL
+03	NULL
|	NULL
tot	NULL
t	NULL
_	NULL
M	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
67	NULL
,	NULL
git-l	NULL
Probe	NULL
:	NULL
-170/-139	NULL
Proteins	NULL
:	NULL
-	NULL
Nuclear	NULL
'\	NULL
TTP	NULL
E	NULL
O	NULL
|	NULL
2	NULL
elle	NULL
$	NULL
m	NULL
$	NULL
a	NULL
N	NULL
N	NULL
N	NULL
a	NULL
S	NULL
L8	NULL
8	NULL
3°	NULL
P.6	NULL
$	NULL
ng	NULL
170/155	NULL
A-	NULL
A-	NULL
A-	NULL
'\°\/\°\O§	NULL
>	NULL
\\	NULL
‘	NULL
*	NULL
Sags	NULL
PMA	NULL
:	NULL
-	NULL
£-	NULL
4+	NULL
-+	NULL
~-	NULL
+	NULL
Ab	NULL
:	NULL
cfeagiet	NULL
*	NULL
--	NULL
C1	NULL
u	NULL
<	NULL
+Spi1	NULL
Sp1-	NULL
>	NULL
M	NULL
``	NULL
my	NULL
Sp3-	NULL
»	NULL
tna	NULL
tad	NULL
bu	NULL
L4	NULL
C4	NULL
-	NULL
»	NULL
C5	NULL
-	NULL
»	NULL
h	NULL
1	NULL
2	NULL
3	NULL
4	NULL
_s	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Purified	NULL
Sp1	NULL
FRs	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

EMSAs	NULL
of	NULL
nuclear	NULL
proteins	NULL
binding	NULL
to	NULL
-170	NULL
to	NULL
-139	NULL
,	NULL
-170	NULL
to	NULL
-155	NULL
,	NULL
and	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotides	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Radiolabeled	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
HeLaS3	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
for	NULL
1	NULL
h	NULL
(	NULL
Jurkat	NULL
)	NULL
or	NULL
5	NULL
h	NULL
(	NULL
HeLaS3	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
,	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
7	NULL
)	NULL
were	NULL
incubated	NULL
either	NULL
with	NULL
no	NULL
competitor	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
with	NULL
25	NULL
ng	NULL
of	NULL
the	NULL
following	NULL
unlabeled	NULL
competitors	NULL
:	NULL
-56	NULL
to	NULL
-34	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
-170	NULL
to	NULL
-139	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
-170	NULL
to	NULL
-155	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
-158	NULL
to	NULL
-142	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
and	NULL
SV40	NULL
Sp1	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Radiolabeled	NULL
-170	NULL
to	NULL
-139	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
-158	NULL
to	NULL
-142	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
-170	NULL
to	NULL
-155	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
and	NULL
SV40	NULL
Sp1	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Radiolabeled	NULL
-170	NULL
to	NULL
-139	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
-170	NULL
to	NULL
-155	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
-158	NULL
to	NULL
-142	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
SV40	NULL
Sp1	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
0.5	NULL
footprinting	NULL
unit	NULL
of	NULL
purified	NULL
human	NULL
Spl	NULL
protein	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
.	NULL

(	NULL
E	NULL
)	NULL
The	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
with	NULL
either	NULL
unrelated	NULL
antibody	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
anti-Sp1	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
anti-Sp2	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
anti-Sp3	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
or	NULL
anti-Sp4	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
antibody	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
radiolabeled	NULL
-170	NULL
to	NULL
-155	NULL
probe	NULL
.	NULL

The	NULL
supershifted	NULL
complex	NULL
by	NULL
anti-Sp1	NULL
antibody	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
asterisk	NULL
.	NULL

RESULTS	NULL
Spl	NULL
,	NULL
Sp3	NULL
,	NULL
and	NULL
PIF	NULL
bind	NULL
to	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
enhancer	NULL
region	NULL
.	NULL

To	NULL
identify	NULL
nuclear	NULL
proteins	NULL
that	NULL
could	NULL
bind	NULL
to	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
enhancer	NULL
region	NULL
,	NULL
we	NULL
performed	NULL
EMSAs	NULL
with	NULL
a	NULL
P-labeled	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
major	NULL
(	NULL
C2	NULL
)	NULL
and	NULL
minor	NULL
(	NULL
C1	NULL
and	NULL
C3	NULL
)	NULL
complexes	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
unstimulated	NULL
Jurkat	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
HeLaS3	NULL
3716	NULL
LIN	NULL
AND	NULL
LEONARD	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
cells	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
enhancer	NULL
region	NULL
to	NULL
respond	NULL
to	NULL
PMA	NULL
stimulation	NULL
in	NULL
Jurkat	NULL
but	NULL
not	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
PMA	NULL
induced	NULL
formation	NULL
of	NULL
two	NULL
new	NULL
complexes	NULL
,	NULL
C4	NULL
and	NULL
CS5	NULL
,	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
not	NULL
in	NULL
those	NULL
from	NULL
HeLa	NULL
cells	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

PMA	NULL
treatment	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
complexes	NULL
C1	NULL
,	NULL
C2	NULL
,	NULL
and	NULL
C3	NULL
(	NULL
lane	NULL
2	NULL
versus	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
C4	NULL
complex	NULL
by	NULL
PMA	NULL
was	NULL
somewhat	NULL
variable	NULL
,	NULL
because	NULL
C4	NULL
was	NULL
sometimes	NULL
detected	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
specificity	NULL
of	NULL
these	NULL
complexes	NULL
and	NULL
to	NULL
examine	NULL
if	NULL
they	NULL
bound	NULL
to	NULL
distinct	NULL
regions	NULL
of	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
,	NULL
we	NULL
performed	NULL
competition	NULL
experiments	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
oligonucleotide	NULL
competed	NULL
with	NULL
the	NULL
formation	NULL
of	NULL
all	NULL
of	NULL
the	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
although	NULL
for	NULL
reasons	NULL
unclear	NULL
,	NULL
the	NULL
competition	NULL
of	NULL
CZ	NULL
was	NULL
less	NULL
effective	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
oligonucleotide	NULL
markedly	NULL
diminished	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
C1	NULL
,	NULL
C2	NULL
,	NULL
C3	NULL
,	NULL
and	NULL
C4	NULL
complexes	NULL
but	NULL
was	NULL
less	NULL
effective	NULL
in	NULL
inhibiting	NULL
formation	NULL
of	NULL
C5	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotide	NULL
competed	NULL
with	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
C4	NULL
and	NULL
C5	NULL
complexes	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
C1	NULL
,	NULL
C2	NULL
,	NULL
and	NULL
C3	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

An	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
Sp1	NULL
site	NULL
abolished	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
C1	NULL
,	NULL
C2	NULL
,	NULL
C3	NULL
,	NULL
and	NULL
C4	NULL
complexes	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
CS	NULL
complex	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
Spl-like	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
complexes	NULL
C1	NULL
to	NULL
C4	NULL
but	NULL
not	NULL
CS	NULL
.	NULL

An	NULL
unrelated	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
-56	NULL
to	NULL
-34	NULL
region	NULL
of	NULL
the	NULL
IL-2RB	NULL
promoter	NULL
that	NULL
is	NULL
known	NULL
to	NULL
bind	NULL
to	NULL
Ets	NULL
family	NULL
proteins	NULL
did	NULL
not	NULL
affect	NULL
any	NULL
of	NULL
the	NULL
complexes	NULL
(	NULL
lane	NULL
3	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

When	NULL
used	NULL
in	NULL
EMSAs	NULL
,	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotide	NULL
exhibited	NULL
a	NULL
single	NULL
PMA-inducible	NULL
complex	NULL
of	NULL
much	NULL
greater	NULL
intensity	NULL
than	NULL
was	NULL
seen	NULL
with	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
DNA	NULL
complexes	NULL
formed	NULL
with	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
with	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
was	NULL
indistinguishable	NULL
from	NULL
that	NULL
with	NULL
the	NULL
SV40	NULL
Sp1	NULL
probe	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
appeared	NULL
to	NULL
have	NULL
two	NULL
subregions	NULL
,	NULL
with	NULL
complexes	NULL
C2	NULL
and	NULL
C3	NULL
binding	NULL
to	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
region	NULL
and	NULL
complex	NULL
C5	NULL
binding	NULL
primarily	NULL
to	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
region	NULL
.	NULL

However	NULL
,	NULL
the	NULL
facts	NULL
that	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
oligonucleotide	NULL
could	NULL
partially	NULL
inhibit	NULL
CS5	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
and	NULL
that	NULL
a	NULL
complex	NULL
comigrating	NULL
with	NULL
C5	NULL
could	NULL
be	NULL
detected	NULL
when	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
oligonucleotide	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
suggest	NULL
that	NULL
both	NULL
regions	NULL
could	NULL
independently	NULL
contribute	NULL
to	NULL
formation	NULL
of	NULL
C5	NULL
.	NULL

C1	NULL
and	NULL
C4	NULL
formation	NULL
appeared	NULL
to	NULL
require	NULL
both	NULL
subregions	NULL
,	NULL
because	NULL
neither	NULL
complex	NULL
was	NULL
detected	NULL
except	NULL
with	NULL
the	NULL
full-length	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
5	NULL
'	NULL
portion	NULL
of	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
containing	NULL
an	NULL
Spl	NULL
binding	NULL
motif	NULL
,	NULL
both	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
and	NULL
-170	NULL
to	NULL
-155	NULL
oligonucleotides	NULL
could	NULL
bind	NULL
purified	NULL
human	NULL
Sp1	NULL
with	NULL
a	NULL
pattern	NULL
indistinguishable	NULL
from	NULL
that	NULL
seen	NULL
with	NULL
the	NULL
SV40	NULL
Sp1	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

1D	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
versus	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotide	NULL
did	NULL
not	NULL
bind	NULL
Spl	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Three	NULL
additional	NULL
closely	NULL
related	NULL
Sp1	NULL
family	NULL
proteins	NULL
(	NULL
Sp2	NULL
,	NULL
Sp3	NULL
,	NULL
and	NULL
Sp4	NULL
)	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
19	NULL
,	NULL
25	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
performed	NULL
EMSAs	NULL
with	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
probe	NULL
and	NULL
antibodies	NULL
specific	NULL
for	NULL
all	NULL
four	NULL
Sp1	NULL
family	NULL
proteins	NULL
to	NULL
determine	NULL
which	NULL
were	NULL
involved	NULL
in	NULL
the	NULL
Sp	NULL
complexes	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

16	NULL
,	NULL
an	NULL
anti-Sp1	NULL
antibody	NULL
supershifted	NULL
most	NULL
of	NULL
the	NULL
major	NULL
complex	NULL
,	NULL
which	NULL
migrated	NULL
with	NULL
a	NULL
slower	NULL
mobility	NULL
(	NULL
lane	NULL
2	NULL
versus	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
an	NULL
anti-Sp3	NULL
antibody	NULL
blocked	NULL
the	NULL
complex	NULL
with	NULL
a	NULL
faster	NULL
mobility	NULL
(	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
whereas	NULL
antibodies	NULL
to	NULL
Sp2	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
Sp4	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

These	NULL
data	NULL
establish	NULL
that	NULL
both	NULL
Spl	NULL
and	NULL
Sp3	NULL
bind	NULL
to	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
region	NULL
,	NULL
the	NULL
PMA-inducible	NULL
factor	NULL
(	NULL
PIF	NULL
)	NULL
in	NULL
the	NULL
C5	NULL
complex	NULL
binds	NULL
to	NULL
the	NULL
-158	NULL
to	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A	NULL
-170/-151	NULL
C	NULL
-158/-139	NULL
Top	NULL
Bottom	NULL
!	NULL

Top	NULL
_	NULL
_	NULL
_Bottom	NULL
|	NULL
m	NULL
w	NULL
I	NULL
5	NULL
|	NULL
9	NULL
Ko	NULL
9	NULL
F0	NULL
9	NULL
K.o	NULL
YC	NULL
«	NULL
prt	NULL
-	NULL
«	NULL
or	NULL
?	NULL

Pw	NULL
e	NULL
poo	NULL
_	NULL
BBG	NULL
«	NULL
-_	NULL
®=®	NULL
-	NULL
e	NULL
®	NULL
®	NULL
«	NULL
~	NULL
o	NULL
w	NULL
«	NULL
o	NULL
__	NULL
P3	NULL
w	NULL
_	NULL
«	NULL
»	NULL
0	NULL
®	NULL
®	NULL
_	NULL
®	NULL
o	NULL
+4	NULL
o	NULL
o*	NULL
l	NULL
g	NULL
:	NULL
:	NULL
v	NULL
ao	NULL
o	NULL
poo	NULL
:	NULL
®	NULL
mee	NULL
O	NULL
e	NULL
on	NULL
us	NULL
O	NULL
o	NULL
n	NULL
L	NULL
bee	NULL
Whe	NULL
e	NULL
bee	NULL
w	NULL
wow	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
sl	NULL
ANG	NULL
}	NULL
5	NULL
Spl	NULL
a	NULL
5	NULL
PIB	NULL
a	NULL
i	NULL
1	NULL
«	NULL
4	NULL
ad	NULL
rererecce	NULL
Ta	NULL
Coagcora	NULL
Geagecagar	NULL
or	NULL
Aﬂﬂg§§8§	NULL
ﬁg	NULL
?	NULL

cercegcar	NULL
corceegrera	NULL
ca	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Methylation	NULL
interference	NULL
analyses	NULL
.	NULL

Double-stranded	NULL
-170	NULL
to	NULL
-151	NULL
(	NULL
A	NULL
)	NULL
and	NULL
-158	NULL
to	NULL
-139	NULL
(	NULL
C	NULL
)	NULL
probes	NULL
were	NULL
end	NULL
labeled	NULL
on	NULL
the	NULL
top	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
or	NULL
bottom	NULL
(	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
strands	NULL
and	NULL
partially	NULL
methylated	NULL
with	NULL
dimethyl	NULL
sulfate	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
the	NULL
methylated	NULL
probes	NULL
.	NULL

For	NULL
both	NULL
panels	NULL
A	NULL
and	NULL
C	NULL
,	NULL
free	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
)	NULL
and	NULL
bound	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
probes	NULL
were	NULL
excised	NULL
in	NULL
situ	NULL
and	NULL
eluted	NULL
from	NULL
the	NULL
gel	NULL
,	NULL
treated	NULL
with	NULL
piperidine	NULL
(	NULL
Fisher	NULL
Scientific	NULL
)	NULL
,	NULL
lyophilized	NULL
,	NULL
resolved	NULL
on	NULL
a	NULL
12	NULL
%	NULL
sequencing	NULL
gel	NULL
,	NULL
and	NULL
autoradiographed	NULL
.	NULL

The	NULL
results	NULL
from	NULL
panels	NULL
A	NULL
and	NULL
C	NULL
are	NULL
summarized	NULL
in	NULL
panels	NULL
B	NULL
and	NULL
D	NULL
,	NULL
respectively	NULL
.	NULL

Strong	NULL
interference	NULL
with	NULL
binding	NULL
due	NULL
to	NULL
methylation	NULL
of	NULL
G	NULL
residues	NULL
is	NULL
indicated	NULL
by	NULL
solid	NULL
circles	NULL
,	NULL
and	NULL
weak	NULL
interference	NULL
with	NULL
binding	NULL
is	NULL
indicated	NULL
by	NULL
open	NULL
circles	NULL
.	NULL

-142	NULL
region	NULL
,	NULL
and	NULL
the	NULL
PMA-inducible	NULL
C4	NULL
complex	NULL
may	NULL
contain	NULL
both	NULL
Sp1	NULL
family	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
and	NULL
PIF	NULL
.	NULL

Compared	NULL
to	NULL
the	NULL
full-length	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
,	NULL
more	NULL
intense	NULL
binding	NULL
activities	NULL
were	NULL
seen	NULL
with	NULL
the	NULL
-170	NULL
to	NULL
-155	NULL
and	NULL
-158	NULL
to	NULL
-142	NULL
probes	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

To	NULL
further	NULL
define	NULL
the	NULL
DNA	NULL
binding	NULL
sequences	NULL
of	NULL
these	NULL
nuclear	NULL
complexes	NULL
,	NULL
we	NULL
performed	NULL
methylation	NULL
interference	NULL
assays	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
data	NULL
obtained	NULL
from	NULL
the	NULL
EMSAs	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
the	NULL
methylation	NULL
interference	NULL
pattern	NULL
obtained	NULL
with	NULL
a	NULL
-170	NULL
to	NULL
-151	NULL
probe	NULL
revealed	NULL
that	NULL
the	NULL
nuclear	NULL
factors	NULL
in	NULL
C2	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
[	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
]	NULL
)	NULL
and	NULL
C3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
indeed	NULL
contacted	NULL
the	NULL
Spl	NULL
motif	NULL
(	NULL
5	NULL
!	NULL

-GTGTGCCGCCCCCAG-3	NULL
'	NULL
)	NULL
between	NULL
-169	NULL
and	NULL
-155	NULL
,	NULL
whereas	NULL
the	NULL
methylation	NULL
interference	NULL
pattern	NULL
obtained	NULL
with	NULL
a	NULL
-158	NULL
to	NULL
-139	NULL
probe	NULL
indicated	NULL
that	NULL
PIF	NULL
contacted	NULL
the	NULL
region	NULL
between	NULL
-155	NULL
and	NULL
-143	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
;	NULL
summarized	NULL
in	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
wild-type	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
efficiently	NULL
competed	NULL
for	NULL
PMA-inducible	NULL
DNA	NULL
binding	NULL
activity	NULL
to	NULL
a	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
3	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
data	NULL
from	NULL
the	NULL
methylation	NULL
interference	NULL
assays	NULL
,	NULL
mutation	NULL
of	NULL
either	NULL
the	NULL
GCG	NULL
residues	NULL
at	NULL
-155	NULL
to	NULL
-153	NULL
into	NULL
CAC	NULL
(	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
GAG	NULL
residues	NULL
at	NULL
-149	NULL
to	NULL
-147	NULL
into	NULL
TCT	NULL
(	NULL
lane	NULL
5	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
of	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotide	NULL
abolished	NULL
its	NULL
ability	NULL
to	NULL
compete	NULL
for	NULL
PIF	NULL
binding	NULL
to	NULL
the	NULL
wild-type	NULL
probe	NULL
,	NULL
and	NULL
neither	NULL
of	NULL
these	NULL
mutant	NULL
oligonucleotides	NULL
could	NULL
bind	NULL
PIF	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
motif	NULL
for	NULL
PIF	NULL
differs	NULL
from	NULL
the	NULL
consensus	NULL
motifs	NULL
of	NULL
other	NULL
known	NULL
PIFs	NULL
,	NULL
including	NULL
AP-1	NULL
(	NULL
TGA	NULL
CTCA	NULL
)	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
GGGRNNYYCC	NULL
)	NULL
(	NULL
1	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
AP-1	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
NF-KB	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
NF-AT	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
binding	NULL
sites	NULL
did	NULL
not	NULL
compete	NULL
for	NULL
PIF	NULL
binding	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
antibodies	NULL
to	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
to	NULL
compete	NULL
for	NULL
NF-AT	NULL
binding	NULL
(	NULL
10	NULL
,	NULL
35	NULL
)	NULL
,	NULL
a	NULL
number	NULL
of	NULL
antibodies	NULL
that	NULL
specifically	NULL
recognize	NULL
c-Fos	NULL
,	NULL
c-Jun	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
A	NULL
-158-142	NULL
WT	NULL
-	NULL
CCAGCGTAGGAGGCA	NULL
-158/142	NULL
Mut-1	NULL
CCAcacTAGGAGGCA	NULL
-158/-142	NULL
Mut2	NULL
CCAGCGTAGtctGCA	NULL
AP-1	NULL
CGCTTGATGACTCAGCCGGAA	NULL
HIV	NULL
xB	NULL
CAAGGGACTTTCCGCT	NULL
NF-AT	NULL
CCCCAAAGAGGAAATTTGTTTCATACAGAA	NULL
B	NULL
C	NULL
Probe	NULL
:	NULL
-158/-142	NULL
-158/-142	NULL
$	NULL
6	NULL
Competitors	NULL
:	NULL
\	NULL
«	NULL
Br	NULL
%	NULL
«	NULL
.	NULL

®	NULL
$	NULL
~S§tg®xgk	NULL
Probe	NULL
:	NULL
@	NULL
rp	NULL
FCI	NULL
PMA	NULL
:	NULL
~=+++	NULL
o	NULL
--	NULL
|b	NULL
}	NULL
PIF-	NULL
»	NULL
-	NULL
twp	NULL
th-	NULL
‘	NULL
aus	NULL
t	NULL
ons	NULL
t	NULL
123	NULL
4	NULL
5	NULL
67	NULL
8	NULL
it	NULL
»	NULL
404¢	NULL
PMA	NULL
:	NULL
-+++++++	NULL
1	NULL
23	NULL
4	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

PIF	NULL
is	NULL
different	NULL
from	NULL
AP-1	NULL
,	NULL
NF-xB	NULL
,	NULL
and	NULL
NF-AT	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequences	NULL
of	NULL
the	NULL
wild-type	NULL
and	NULL
mutant	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotides	NULL
(	NULL
mutations	NULL
are	NULL
underlined	NULL
and	NULL
in	NULL
lowercase	NULL
)	NULL
,	NULL
and	NULL
AP-1	NULL
,	NULL
HIV	NULL
B	NULL
,	NULL
and	NULL
NF-AT	NULL
oligonucleotides	NULL
.	NULL

The	NULL
NF-AT	NULL
sequence	NULL
is	NULL
from	NULL
the	NULL
murine	NULL
IL-2	NULL
promoter	NULL
(	NULL
31	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
,	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
8	NULL
)	NULL
were	NULL
incubated	NULL
either	NULL
with	NULL
no	NULL
competitor	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
with	NULL
25	NULL
ng	NULL
of	NULL
the	NULL
following	NULL
unlabeled	NULL
competitors	NULL
:	NULL
wild	NULL
type	NULL
(	NULL
WT	NULL
;	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
mutant	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotides	NULL
or	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
AP-1	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
HIV	NULL
«	NULL
B	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
or	NULL
NF-AT	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
sites	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
radiolabeled	NULL
wild-type	NULL
(	NULL
WT	NULL
;	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
mutant	NULL
(	NULL
Mut-1	NULL
in	NULL
lane	NULL
3	NULL
,	NULL
Mut-2	NULL
in	NULL
lane	NULL
4	NULL
)	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotide	NULL
probes	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
2	NULL
h	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

proteins	NULL
,	NULL
or	NULL
Fos	NULL
or	NULL
Jun	NULL
family	NULL
proteins	NULL
did	NULL
not	NULL
affect	NULL
PIF	NULL
binding	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
diminishing	NULL
the	NULL
possibility	NULL
that	NULL
AP-1	NULL
family	NULL
proteins	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
PIF	NULL
complex	NULL
.	NULL

PIF	NULL
binding	NULL
activity	NULL
is	NULL
rapidly	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
is	NULL
required	NULL
for	NULL
its	NULL
production	NULL
.	NULL

A	NULL
kinetic	NULL
analysis	NULL
revealed	NULL
that	NULL
PIF	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
detectable	NULL
as	NULL
early	NULL
as	NULL
30	NULL
min	NULL
after	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
was	NULL
maximal	NULL
between	NULL
1	NULL
and	NULL
2	NULL
h	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
and	NULL
was	NULL
sustained	NULL
at	NULL
a	NULL
high	NULL
level	NULL
for	NULL
at	NULL
least	NULL
23	NULL
h	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
PIF	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
only	NULL
very	NULL
weakly	NULL
and	NULL
transiently	NULL
detected	NULL
in	NULL
HeLa	NULL
nuclear	NULL
extracts	NULL
at	NULL
1	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
2	NULL
h	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
following	NULL
PMA	NULL
treatment	NULL
,	NULL
but	NULL
at	NULL
a	NULL
much	NULL
lower	NULL
level	NULL
than	NULL
that	NULL
seen	NULL
with	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
transient	NULL
weak	NULL
activation	NULL
of	NULL
PIF	NULL
in	NULL
HeLaS3	NULL
cells	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
activate	NULL
a	NULL
CAT	NULL
reporter	NULL
construct	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
in	NULL
these	NULL
cells	NULL
with	NULL
either	NULL
of	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
-170	NULL
to	NULL
-139	NULL
(	NULL
30	NULL
)	NULL
regions	NULL
.	NULL

Because	NULL
PIF	NULL
was	NULL
rapidly	NULL
induced	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
was	NULL
required	NULL
for	NULL
its	NULL
induction	NULL
or	NULL
whether	NULL
like	NULL
NF-	NULL
«	NULL
xB	NULL
,	NULL
it	NULL
was	NULL
present	NULL
in	NULL
a	NULL
latent	NULL
form	NULL
in	NULL
the	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
cycloheximide	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

Cycloheximide	NULL
did	NULL
not	NULL
induce	NULL
PIF	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
PMA	NULL
to	NULL
induce	NULL
REGULATION	NULL
OF	NULL
IL-Z2RB	NULL
PROMOTER	NULL
BY	NULL
Egr1	NULL
-	NULL
3717	NULL
PMA	NULL
(	NULL
Hr	NULL
)	NULL
:	NULL
bos	NULL
1	NULL
2	NULL
a	NULL
2s	NULL
Nuclear	NULL
Extract	NULL
:	NULL
Jurkat	NULL
Hela	NULL
PMA	NULL
(	NULL
hr	NULL
)	NULL
:	NULL
0	NULL
2	NULL
0051	NULL
2	NULL
4	NULL
23	NULL
PIF	NULL
+	NULL
M	NULL
&	NULL
will	NULL
like	NULL
Probe	NULL
:	NULL
_	NULL
-158/-142	NULL
12	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
U	NULL
In	NULL
dun	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
C	NULL
D	NULL
E	NULL
PBL	NULL
ags	NULL
Cag	NULL
s	NULL
Sat	NULL
a	NULL
C	NULL
&	NULL
&	NULL
x	NULL
is	NULL
RS	NULL
gator	NULL
y	NULL
$	NULL
3ES	NULL
-	NULL
$	NULL
3FS	NULL
Cogas	NULL
pma	NULL
-¥	NULL
-¥	NULL
&	NULL
adi	NULL
iin	NULL
(	NULL
“	NULL
HunkNF-KB	NULL
PFE	NULL
n	NULL
E	NULL
12	NULL
3	NULL
4	NULL
1	NULL
2	NULL
8	NULL
4	NULL
12	NULL
3	NULL
4	NULL
12	NULL
34	NULL
-158/-142	NULL
HIV	NULL
B	NULL
-158/-142	NULL
-158/-142	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

PIF	NULL
is	NULL
induced	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
,	NULL
and	NULL
the	NULL
induction	NULL
in	NULL
Jurkat	NULL
cells	NULL
is	NULL
abolished	NULL
by	NULL
cycloheximide	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
30	NULL
min	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
2	NULL
h	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
4	NULL
h	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
23	NULL
h	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
2	NULL
h	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
HeLaS3	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
30	NULL
min	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
2	NULL
h	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
4	NULL
h	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
23	NULL
h	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
panel	NULL
is	NULL
a	NULL
longer	NULL
exposure	NULL
of	NULL
the	NULL
upper	NULL
lanes	NULL
3	NULL
to	NULL
8	NULL
,	NULL
and	NULL
PMA-inducible	NULL
DNA	NULL
binding	NULL
activities	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
cycloheximide	NULL
per	NULL
ml	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
PMA	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
both	NULL
cycloheximide	NULL
and	NULL
PMA	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Radiolabeled	NULL
HIV	NULL
«	NULL
B	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
same	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
used	NULL
in	NULL
panel	NULL
B	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
PBLs	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
1	NULL
mg	NULL
of	NULL
PHA	NULL
per	NULL
ml	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
2	NULL
nM	NULL
IL-2	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

(	NULL
F	NULL
)	NULL
Constitutive	NULL
PIF	NULL
binding	NULL
activity	NULL
in	NULL
HTLV-1-transformed	NULL
MT-2	NULL
cells	NULL
.	NULL

Radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
MT-2	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
cells	NULL
.	NULL

PIF	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
1	NULL
)	NULL
,	NULL
cycloheximide	NULL
not	NULL
only	NULL
induced	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
in	NULL
fact	NULL
superinduced	NULL
NF-kB	NULL
binding	NULL
activity	NULL
by	NULL
PMA	NULL
(	NULL
lane	NULL
4	NULL
versus	NULL
3	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
production	NULL
of	NULL
PIF	NULL
.	NULL

PIF	NULL
binding	NULL
activity	NULL
is	NULL
induced	NULL
by	NULL
PMA	NULL
but	NULL
not	NULL
by	NULL
PHA	NULL
or	NULL
IL-2	NULL
in	NULL
normal	NULL
PBLs	NULL
and	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
HTLV-1-transformed	NULL
MT-2	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
its	NULL
induction	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
PIF	NULL
binding	NULL
activity	NULL
was	NULL
induced	NULL
by	NULL
PMA	NULL
in	NULL
normal	NULL
PBLs	NULL
(	NULL
Fig	NULL
.	NULL

4E	NULL
,	NULL
lane	NULL
2	NULL
versus	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
whereas	NULL
a	NULL
single	NULL
major	NULL
PIF	NULL
complex	NULL
was	NULL
detected	NULL
in	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

4F	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
two	NULL
complexes	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
nuclear	NULL
3718	NULL
LIN	NULL
AND	NULL
LEONARD	NULL
extracts	NULL
from	NULL
PBLs	NULL
isolated	NULL
from	NULL
three	NULL
independent	NULL
donors	NULL
(	NULL
Fig	NULL
.	NULL

4E	NULL
,	NULL
lane	NULL
2	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
the	NULL
upper	NULL
complex	NULL
comigrated	NULL
with	NULL
the	NULL
Jurkat	NULL
PIF	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
basis	NULL
for	NULL
the	NULL
added	NULL
complex	NULL
in	NULL
PBLs	NULL
is	NULL
unclear	NULL
and	NULL
requires	NULL
further	NULL
investigation	NULL
.	NULL

Neither	NULL
complex	NULL
was	NULL
induced	NULL
by	NULL
PHA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
IL-2	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
unlike	NULL
NF-kB	NULL
,	NULL
PIF	NULL
binding	NULL
activity	NULL
appears	NULL
to	NULL
be	NULL
mainly	NULL
induced	NULL
by	NULL
PMA	NULL
.	NULL

Many	NULL
cellular	NULL
genes	NULL
are	NULL
activated	NULL
in	NULL
HTLV-1-infected	NULL
T	NULL
cells	NULL
by	NULL
a	NULL
40-kDa	NULL
viral	NULL
transactivator	NULL
Tax	NULL
protein	NULL
of	NULL
HTLV-1	NULL
(	NULL
32	NULL
,	NULL
51	NULL
)	NULL
.	NULL

Tax	NULL
activates	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
by	NULL
modulating	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
including	NULL
AP-1	NULL
,	NULL
ATF/CREB	NULL
,	NULL
and	NULL
NF-kB	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
PMA-inducible	NULL
transcription	NULL
factors	NULL
,	NULL
like	NULL
c-fos	NULL
and	NULL
NF-KB	NULL
,	NULL
are	NULL
constitutively	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
HTLV-1-transformed	NULL
MT	NULL
-2	NULL
cells	NULL
and	NULL
are	NULL
known	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
Tax	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
51	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
whether	NULL
PIF	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
affected	NULL
in	NULL
MT-2	NULL
cells	NULL
.	NULL

Constitutive	NULL
PIF	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
MT-2	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

4F	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
and	NULL
it	NULL
was	NULL
also	NULL
modestly	NULL
increased	NULL
after	NULL
PMA	NULL
treatment	NULL
(	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
HTLV-1	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
might	NULL
activate	NULL
PIF	NULL
via	NULL
a	NULL
protein	NULL
kinase	NULL
C-dependent	NULL
pathway	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
molecular	NULL
mass	NULL
of	NULL
PIF	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
PIF	NULL
,	NULL
we	NULL
performed	NULL
Southwestern	NULL
assays	NULL
with	NULL
the	NULL
-158	NULL
to	NULL
-139	NULL
probe	NULL
.	NULL

Two	NULL
proteins	NULL
migrating	NULL
at	NULL
82	NULL
and	NULL
60	NULL
kDa	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
detected	NULL
with	NULL
a	NULL
wild-type	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
not	NULL
mutant	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
probe	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
after	NULL
PMA	NULL
stimulation	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
from	NULL
unstimulated	NULL
MT-2	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

No	NULL
proteins	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

A	NULL
constitutively	NULL
expressed	NULL
120-kDa	NULL
protein	NULL
was	NULL
detected	NULL
by	NULL
both	NULL
wild-type	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
mutant	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
probes	NULL
,	NULL
indicating	NULL
that	NULL
it	NULL
binds	NULL
to	NULL
the	NULL
sequences	NULL
unrelated	NULL
to	NULL
the	NULL
PIF	NULL
site	NULL
.	NULL

PIF	NULL
is	NULL
Egr-1	NULL
.	NULL

The	NULL
rapid	NULL
induction	NULL
of	NULL
PIF	NULL
and	NULL
the	NULL
requirement	NULL
of	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
for	NULL
its	NULL
DNA	NULL
binding	NULL
activity	NULL
suggested	NULL
that	NULL
PIF	NULL
was	NULL
encoded	NULL
by	NULL
an	NULL
immediate-early	NULL
gene	NULL
.	NULL

Because	NULL
PIF	NULL
contains	NULL
82-	NULL
and	NULL
60-kDa	NULL
DNA	NULL
binding	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
PIF	NULL
was	NULL
related	NULL
to	NULL
the	NULL
Zn	NULL
finger-containing	NULL
Egr	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
which	NULL
are	NULL
immediate-early	NULL
gene	NULL
products	NULL
induced	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
stimuli	NULL
,	NULL
including	NULL
PMA	NULL
,	NULL
and	NULL
which	NULL
have	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
80	NULL
to	NULL
82	NULL
kDa	NULL
(	NULL
5	NULL
,	NULL
44	NULL
)	NULL
.	NULL

In	NULL
EMSAs	NULL
with	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
,	NULL
an	NULL
Egr-1	NULL
binding	NULL
site	NULL
(	NULL
EBS-1	NULL
;	NULL
CGCCCCCGC	NULL
)	NULL
(	NULL
5	NULL
)	NULL
bound	NULL
to	NULL
a	NULL
PIF	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
3	NULL
)	NULL
that	NULL
comigrated	NULL
with	NULL
the	NULL
PIF	NULL
seen	NULL
with	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
core	NULL
DNA	NULL
binding	NULL
sites	NULL
differed	NULL
(	NULL
5'-GCGTAGGAGGCA	NULL
G-3	NULL
'	NULL
for	NULL
PIF	NULL
and	NULL
5-CGCCCCCGC-3	NULL
'	NULL
for	NULL
Egr-1	NULL
)	NULL
,	NULL
the	NULL
unlabeled	NULL
-158	NULL
to	NULL
-142	NULL
and	NULL
EBS-1	NULL
oligonucleotides	NULL
nevertheless	NULL
inhibited	NULL
PIF	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
versus	NULL
lane	NULL
1	NULL
and	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
versus	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
with	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
oligonucleotide	NULL
being	NULL
less	NULL
efficient	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
versus	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Egr	NULL
family	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
are	NULL
likely	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
PMA-inducible	NULL
DNA	NULL
complex	NULL
.	NULL

This	NULL
notion	NULL
was	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
anti-Egr-1	NULL
antisera	NULL
either	NULL
abolished	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
or	NULL
supershifted	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
PMA-inducible	NULL
DNA	NULL
binding	NULL
activity	NULL
to	NULL
either	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
or	NULL
EBS-1	NULL
probe	NULL
,	NULL
whereas	NULL
antisera	NULL
specific	NULL
for	NULL
other	NULL
Egr	NULL
family	NULL
proteins	NULL
,	NULL
including	NULL
Egr-2	NULL
,	NULL
Egr-3	NULL
,	NULL
and	NULL
Wilm	NULL
's	NULL
tumor	NULL
antigen	NULL
,	NULL
did	NULL
not	NULL
affect	NULL
protein	NULL
binding	NULL
to	NULL
either	NULL
probe	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
establish	NULL
that	NULL
the	NULL
PIF	NULL
that	NULL
bound	NULL
to	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
region	NULL
in	NULL
the	NULL
human	NULL
IL-2RB	NULL
promoter	NULL
is	NULL
Egr-1	NULL
,	NULL
and	NULL
we	NULL
therefore	NULL
redenote	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
region	NULL
PIF	NULL
as	NULL
an	NULL
Egr-1	NULL
site	NULL
.	NULL

Although	NULL
the	NULL
consensus	NULL
DNA	NULL
binding	NULL
site	NULL
for	NULL
Egr-1	NULL
was	NULL
defined	NULL
as	NULL
GCGKGG	NULL
GCG	NULL
(	NULL
8	NULL
)	NULL
,	NULL
our	NULL
data	NULL
show	NULL
that	NULL
Egr-1	NULL
can	NULL
recognize	NULL
a	NULL
DNA	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

$	NULL
)	NULL
``	NULL
Probe	NULL
:	NULL
x	NULL
&	NULL
Probe	NULL
WT	NULL
Mut	NULL
1T	NULL
frm	NULL
:	NULL
PMA	NULL
:	NULL
-	NULL
4+	NULL
-+	NULL
pma	NULL
-	NULL
-¥	NULL
-	NULL
+	NULL
kDa	NULL
be	NULL
I	NULL
wad	NULL
--	NULL
t	NULL
``	NULL
H	NULL
*	NULL
wor	NULL
wee	NULL
kDa	NULL
*	NULL
-_-97.4-	NULL
Me	NULL
=	NULL
«	NULL
g2	NULL
-+-B9	NULL
m	NULL
46	NULL
1	NULL
2	NULL
3	NULL
4	NULL
w	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Probe	NULL
:	NULL
-158/-142	NULL
_	NULL
EBS-1	NULL
:	NULL
i	NULL
e	NULL
_	NULL
Iﬁ	NULL
Probe	NULL
:	NULL
158/-142_EBS-1	NULL
w	NULL
©	NULL
;	NULL
D	NULL
©	NULL
.N	NULL
Il	NULL
£65	NULL
65:69	NULL
”	NULL
Antibodies	NULL
:	NULL
-	NULL
-	NULL
3°	NULL
.°	NULL
<	NULL
3	NULL
ompetitor	NULL
:	NULL
+	NULL
N	NULL
f	NULL
f	NULL
PMA	NULL
:	NULL
-++-	NULL
++	NULL
--	NULL
'	NULL
Mos	NULL
(	NULL
MBH	NULL
eyr	NULL
--	NULL
'	NULL
W	NULL
M	NULL
tubs	NULL
12	NULL
3	NULL
4	NULL
5	NULL
6	NULL
hinaus	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Characterization	NULL
of	NULL
PIF	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Southwestern	NULL
analysis	NULL
with	NULL
the	NULL
-158	NULL
to	NULL
-139	NULL
probe	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
were	NULL
analyzed	NULL
by	NULL
Southwestern	NULL
assay	NULL
with	NULL
either	NULL
radiolabeled	NULL
wild-type	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
mutant	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
-158	NULL
to	NULL
-139	NULL
probes	NULL
.	NULL

A	NULL
120-kDa	NULL
band	NULL
constitutively	NULL
present	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
asterisk	NULL
.	NULL

Molecular	NULL
masses	NULL
were	NULL
determined	NULL
by	NULL
comparisons	NULL
with	NULL
the	NULL
mobilities	NULL
of	NULL
prestained	NULL
molecular	NULL
markers	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PIF	NULL
comigrates	NULL
with	NULL
Egr	NULL
family	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
from	NULL
EMSA	NULL
with	NULL
radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
canonical	NULL
Egr	NULL
binding	NULL
motif	NULL
(	NULL
EBS-1	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
probes	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
unstimulated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Inhibition	NULL
of	NULL
PIF	NULL
DNA	NULL
binding	NULL
activity	NULL
by	NULL
Egr	NULL
DNA	NULL
binding	NULL
site	NULL
.	NULL

Results	NULL
are	NULL
from	NULL
EMSA	NULL
with	NULL
radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
and	NULL
the	NULL
canonical	NULL
Egr	NULL
binding	NULL
motif	NULL
(	NULL
EBS-1	NULL
;	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
probes	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
unstimulated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
the	NULL
unlabeled	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
or	NULL
the	NULL
Egr	NULL
binding	NULL
site	NULL
(	NULL
EBS-1	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
probes	NULL
.	NULL

(	NULL
D	NULL
)	NULL
PIF	NULL
is	NULL
recognized	NULL
by	NULL
anti-Egr-1	NULL
antiserum	NULL
.	NULL

Results	NULL
are	NULL
from	NULL
EMSA	NULL
with	NULL
radiolabeled	NULL
-158	NULL
to	NULL
-142	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
and	NULL
the	NULL
canonical	NULL
Egr	NULL
binding	NULL
motif	NULL
(	NULL
EBS-1	NULL
;	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
probes	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
unstimulated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
probes	NULL
,	NULL
the	NULL
extracts	NULL
were	NULL
incubated	NULL
either	NULL
with	NULL
anti-Stat5	NULL
(	NULL
Stat5	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
as	NULL
a	NULL
control	NULL
antiserum	NULL
or	NULL
with	NULL
anti-Egr-1	NULL
(	NULL
Egr-1	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
panels	NULL
B	NULL
to	NULL
D	NULL
,	NULL
a	NULL
constitutive	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
detected	NULL
by	NULL
the	NULL
EBS-1	NULL
probe	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
asterisks	NULL
.	NULL

sequence	NULL
very	NULL
different	NULL
from	NULL
the	NULL
consensus	NULL
.	NULL

Because	NULL
a	NULL
60-	NULL
to	NULL
62-kDa	NULL
truncated	NULL
form	NULL
of	NULL
Egr-1	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
(	NULL
15	NULL
)	NULL
and	NULL
the	NULL
anti-Egr-1	NULL
antiserum	NULL
abolishes	NULL
PIF	NULL
binding	NULL
to	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
,	NULL
we	NULL
speculate	NULL
that	NULL
the	NULL
60-kDa	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
A	NULL
;	NULL
170	NULL
Sp1	NULL
Egr1	NULL
189	NULL
wT	NULL
TGTGTGCCECCCCCAGCGTAGGAGGCAGATCT	NULL
Spt-m	NULL
TGTGTGCCGatCCCAGCGTAGGAGGCAGATCT	NULL
Egr-M	NULL
TGTGTGCCECCCCCAGCGTAGtctGCAGATCT	NULL
Spt/egrM	NULL
-	NULL
TGTGTGCCGatCCCAGCGTAGtctCCAGATCT	NULL
B	NULL
-170/-139	NULL
C	NULL
O-	NULL
OJ	NULL
8	NULL
C	NULL
Probe	NULL
:	NULL
¢	NULL
a	NULL
0	NULL
&	NULL
6	NULL
?	NULL

“	NULL
-	NULL
x1	NULL
9C	NULL
22	NULL
€	NULL
0	NULL
42°80	NULL
a	NULL
Antibody	NULL
:	NULL
C	NULL
G	NULL
@	NULL
C	NULL
5	NULL
&	NULL
l_	NULL
'	NULL
1|—ll—|	NULL
r—llﬁrﬁ	NULL
Pma	NULL
:	NULL
=+	NULL
C44	NULL
02+	NULL
cat	NULL
(	NULL
rpc	NULL
oz	NULL
»	NULL
.	NULL

Sn	NULL
E.	NULL
but	NULL
Ga	NULL
luk	NULL
lak	NULL
bay	NULL
fy	NULL
.	NULL

-	NULL
bo	NULL
bat	NULL
but	NULL
tut	NULL
hut	NULL
at	NULL
*	NULL
£91	NULL
An	NULL
betic	NULL
uathdib	NULL
1	NULL
2	NULL
8	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
hat	NULL
fud	NULL
bas	NULL
tnd	NULL
bat	NULL
ane	NULL
1	NULL
2	NULL
s	NULL
4	NULL
5	NULL
607	NULL
8	NULL
9	NULL
40	NULL
1112	NULL
L______J	NULL
Probe	NULL
wT	NULL
Mut	NULL
-170/-139	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Egr-1	NULL
binds	NULL
to	NULL
both	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
sites	NULL
at	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Sequences	NULL
of	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
,	NULL
Sp1	NULL
mutant	NULL
(	NULL
Sp1-M	NULL
)	NULL
,	NULL
Egr-1	NULL
mutant	NULL
(	NULL
Egr-M	NULL
)	NULL
,	NULL
and	NULL
Sp1	NULL
plus	NULL
Egr-1	NULL
mutant	NULL
(	NULL
Sp1/Egr-M	NULL
)	NULL
-170	NULL
to	NULL
-139	NULL
oligonucleotides	NULL
,	NULL
show	NULL
ing	NULL
the	NULL
Spl	NULL
and	NULL
Egr-1	NULL
motifs	NULL
,	NULL
and	NULL
mutated	NULL
nucleotides	NULL
(	NULL
underlined	NULL
in	NULL
lowercase	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
with	NULL
radiolabeled	NULL
wild-type	NULL
(	NULL
WT	NULL
;	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
Sp1	NULL
mutant	NULL
(	NULL
Sp1-M	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
Egr-1	NULL
mutant	NULL
(	NULL
Egr-M	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
and	NULL
Sp1	NULL
plus	NULL
Egr-1	NULL
mutant	NULL
(	NULL
Sp1/Egr-M	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
probes	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
unstimulated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
with	NULL
radiolabeled	NULL
wild-type	NULL
(	NULL
WT	NULL
;	NULL
lanes	NULL
1	NULL
to	NULL
6	NULL
)	NULL
and	NULL
Egr-1	NULL
mutant	NULL
(	NULL
Mut	NULL
;	NULL
lanes	NULL
7	NULL
to	NULL
12	NULL
)	NULL
-170	NULL
to	NULL
-139	NULL
probes	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
unstimulated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
and	NULL
11	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
8	NULL
,	NULL
10	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

Prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
probes	NULL
,	NULL
the	NULL
extracts	NULL
were	NULL
incubated	NULL
either	NULL
with	NULL
control	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
,	NULL
anti-Egr-1	NULL
(	NULL
Egr-1	NULL
;	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
)	NULL
,	NULL
or	NULL
anti-Sp1	NULL
(	NULL
Sp1	NULL
;	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
,	NULL
11	NULL
,	NULL
and	NULL
12	NULL
)	NULL
antiserum	NULL
.	NULL

The	NULL
anti-Sp1	NULL
supershifted	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
an	NULL
asterisk	NULL
.	NULL

protein	NULL
detected	NULL
by	NULL
Southwestern	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
might	NULL
be	NULL
a	NULL
truncated	NULL
form	NULL
of	NULL
Egr-1	NULL
.	NULL

The	NULL
Sp	NULL
site	NULL
also	NULL
binds	NULL
to	NULL
Egr-1	NULL
,	NULL
and	NULL
the	NULL
integrity	NULL
of	NULL
both	NULL
Sp	NULL
and	NULL
Egr-1	NULL
sites	NULL
is	NULL
essential	NULL
for	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
.	NULL

We	NULL
next	NULL
evaluated	NULL
how	NULL
mutation	NULL
of	NULL
the	NULL
Sp	NULL
and/or	NULL
Egr-1	NULL
binding	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
affected	NULL
the	NULL
formation	NULL
of	NULL
each	NULL
complex	NULL
with	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
Sp	NULL
site	NULL
abolished	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
C1	NULL
,	NULL
C3	NULL
,	NULL
and	NULL
C4	NULL
and	NULL
greatly	NULL
diminished	NULL
that	NULL
of	NULL
C2	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
whereas	NULL
that	NULL
of	NULL
C5	NULL
was	NULL
actually	NULL
increased	NULL
,	NULL
suggesting	NULL
that	NULL
Spl	NULL
and/or	NULL
Sp3	NULL
have	NULL
higher	NULL
DNA	NULL
binding	NULL
affinities	NULL
to	NULL
the	NULL
wild-type	NULL
oligonucleotide	NULL
and	NULL
probably	NULL
interfere	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
Egr-1	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
Egr-1	NULL
site	NULL
abolished	NULL
the	NULL
C1	NULL
and	NULL
C4	NULL
complexes	NULL
,	NULL
but	NULL
as	NULL
expected	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
CZ	NULL
and	NULL
C3	NULL
complexes	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
mutation	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
PMA-inducible	NULL
CS	NULL
complex	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
Egr-1	NULL
site	NULL
at	NULL
-158	NULL
to	NULL
-142	NULL
,	NULL
this	NULL
factor	NULL
likely	NULL
recognizes	NULL
other	NULL
sequences	NULL
within	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
,	NULL
consistent	NULL
with	NULL
our	NULL
earlier	NULL
observation	NULL
that	NULL
both	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
and	NULL
-170	NULL
to	NULL
-155	NULL
oligonucleotides	NULL
could	NULL
inhibit	NULL
CS5	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
mutation	NULL
of	NULL
both	NULL
Sp	NULL
and	NULL
Egr-1	NULL
sites	NULL
abolished	NULL
all	NULL
of	NULL
the	NULL
complexes	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
C4	NULL
and	NULL
CS5	NULL
complexes	NULL
both	NULL
contained	NULL
Egr-1	NULL
and	NULL
whether	NULL
the	NULL
PIF	NULL
bound	NULL
to	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
containing	NULL
a	NULL
mutation	NULL
at	NULL
the	NULL
Egr-1	NULL
site	NULL
was	NULL
also	NULL
Egr-1	NULL
,	NULL
we	NULL
performed	NULL
EMSA	NULL
with	NULL
anti-Egr-1	NULL
antiserum	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
REGULATION	NULL
OF	NULL
IL-Z2RB	NULL
PROMOTER	NULL
BY	NULL
Egr1	NULL
-	NULL
3719	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
the	NULL
anti-Egr-1	NULL
antiserum	NULL
abolished	NULL
the	NULL
formation	NULL
of	NULL
both	NULL
the	NULL
C4	NULL
and	NULL
CS5	NULL
complexes	NULL
(	NULL
lane	NULL
4	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
PMA-inducible	NULL
complex	NULL
bound	NULL
to	NULL
the	NULL
Egr-1	NULL
mutant	NULL
-170	NULL
to	NULL
-139	NULL
probe	NULL
was	NULL
also	NULL
recognized	NULL
by	NULL
anti-Egr-1	NULL
antiserum	NULL
(	NULL
lane	NULL
10	NULL
versus	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
Egr-1	NULL
may	NULL
bind	NULL
to	NULL
the	NULL
Sp	NULL
site	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
similarity	NULL
between	NULL
the	NULL
Egr-1	NULL
and	NULL
Sp	NULL
sites	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
all	NULL
three	NULL
probes	NULL
were	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
,	NULL
anti-Sp1	NULL
antiserum	NULL
only	NULL
supershifted	NULL
the	NULL
C2	NULL
complex	NULL
and	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
Egr-1	NULL
binding	NULL
.	NULL

Together	NULL
with	NULL
the	NULL
results	NULL
of	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
these	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
Sp	NULL
site	NULL
not	NULL
only	NULL
binds	NULL
to	NULL
Sp1	NULL
and	NULL
Sp3	NULL
but	NULL
also	NULL
binds	NULL
to	NULL
Egr-1	NULL
.	NULL

In	NULL
the	NULL
context	NULL
of	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
with	NULL
the	NULL
heter-ologous	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
Sp1	NULL
site	NULL
diminished	NULL
basal	NULL
enhancer	NULL
activity	NULL
but	NULL
had	NULL
less	NULL
of	NULL
an	NULL
effect	NULL
on	NULL
the	NULL
fold	NULL
induction	NULL
by	NULL
PMA	NULL
;	NULL
mutation	NULL
of	NULL
both	NULL
sites	NULL
was	NULL
required	NULL
to	NULL
significantly	NULL
diminish	NULL
PMA-inducible	NULL
enhancer	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

In	NULL
the	NULL
context	NULL
of	NULL
the	NULL
-548	NULL
to	NULL
+97	NULL
IL-2RB	NULL
promoter	NULL
,	NULL
the	NULL
greatest	NULL
effect	NULL
was	NULL
also	NULL
seen	NULL
when	NULL
both	NULL
Spl	NULL
and	NULL
Egr-1	NULL
sites	NULL
were	NULL
simultaneously	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
both	NULL
of	NULL
the	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
.	NULL

Since	NULL
much	NULL
less	NULL
endogenous	NULL
Egr-1	NULL
was	NULL
detected	NULL
in	NULL
HeLaS3	NULL
cells	NULL
than	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
we	NULL
next	NULL
evaluated	NULL
whether	NULL
overexpression	NULL
of	NULL
Egr-1	NULL
in	NULL
HeLaS3	NULL
cells	NULL
could	NULL
drive	NULL
expression	NULL
of	NULL
the	NULL
IL-2RB	NULL
constructs	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
pTKB-170/-139	NULL
reporter	NULL
construct	NULL
was	NULL
activated	NULL
by	NULL
Egr-1	NULL
,	NULL
and	NULL
activity	NULL
was	NULL
diminished	NULL
when	NULL
both	NULL
of	NULL
the	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
sites	NULL
were	NULL
mutated	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
there	NULL
was	NULL
very	NULL
little	NULL
,	NULL
if	NULL
any	NULL
,	NULL
PMA	NULL
inducibility	NULL
whether	NULL
the	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
%	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
0.5	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
serum	NULL
,	NULL
indicating	NULL
that	NULL
overexpression	NULL
of	NULL
Egr-1	NULL
in	NULL
HeLaS3	NULL
cells	NULL
obviated	NULL
the	NULL
need	NULL
for	NULL
PMA	NULL
treatment	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
induction	NULL
was	NULL
seen	NULL
with	NULL
the	NULL
-548	NULL
to	NULL
+97	NULL
IL-2RB	NULL
promoter	NULL
construct	NULL
,	NULL
even	NULL
when	NULL
both	NULL
Ets-1	NULL
and	NULL
GABPs	NULL
were	NULL
also	NULL
coexpressed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
additional	NULL
lineage-restricted	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
are	NULL
required	NULL
for	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
importance	NULL
of	NULL
both	NULL
Sp	NULL
and	NULL
Egr-1	NULL
sites	NULL
at	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
for	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
Sp1	NULL
can	NULL
form	NULL
complexes	NULL
with	NULL
either	NULL
itself	NULL
or	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
see	NULL
Discussion	NULL
)	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
Sp1	NULL
could	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
Egr-1	NULL
to	NULL
regulate	NULL
the	NULL
IL-2RB	NULL
promoter	NULL
.	NULL

In	NULL
coimmunoprecipitation	NULL
experiments	NULL
,	NULL
we	NULL
found	NULL
that	NULL
Egr-1	NULL
could	NULL
be	NULL
precipitated	NULL
by	NULL
anti-Spl	NULL
antiserum	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
versus	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
Egr-1	NULL
coimmunoprecipitated	NULL
correlated	NULL
with	NULL
the	NULL
expression	NULL
level	NULL
of	NULL
Egr-1	NULL
in	NULL
the	NULL
cells	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
possibility	NULL
that	NULL
coimmunoprecipitation	NULL
of	NULL
Egr-1	NULL
by	NULL
anti-Sp1	NULL
antiserum	NULL
required	NULL
the	NULL
presence	NULL
of	NULL
DNA	NULL
,	NULL
total	NULL
cell	NULL
lysates	NULL
were	NULL
incubated	NULL
with	NULL
ethidium	NULL
bromide	NULL
prior	NULL
to	NULL
immunoprecipitation	NULL
to	NULL
eliminate	NULL
DNA-dependent	NULL
protein-protein	NULL
interactions	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Anti-Spl	NULL
antiserum	NULL
was	NULL
still	NULL
able	NULL
to	NULL
efficiently	NULL
coprecipitate	NULL
Egr-1	NULL
proteins	NULL
even	NULL
after	NULL
treatment	NULL
of	NULL
the	NULL
lysates	NULL
with	NULL
ethidium	NULL
bromide	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
although	NULL
the	NULL
amounts	NULL
of	NULL
Egr-1	NULL
coprecipitated	NULL
by	NULL
anti-Sp1	NULL
antiserum	NULL
were	NULL
somewhat	NULL
smaller	NULL
than	NULL
that	NULL
seen	NULL
in	NULL
the	NULL
lysate	NULL
without	NULL
ethidium	NULL
bromide	NULL
treatment	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
versus	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
both	NULL
DNA	NULL
-independent	NULL
and	NULL
-de-pendent	NULL
interactions	NULL
of	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
exist	NULL
and	NULL
also	NULL
imply	NULL
that	NULL
the	NULL
Sp1-Egr-1	NULL
complex	NULL
can	NULL
simultaneously	NULL
occupy	NULL
both	NULL
Sp	NULL
and	NULL
Egr-1	NULL
sites	NULL
at	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
,	NULL
thus	NULL
regulating	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
characterized	NULL
a	NULL
PMA-inducible	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
human	NULL
IL-ZRB	NULL
promoter	NULL
region	NULL
and	NULL
have	NULL
shown	NULL
that	NULL
it	NULL
3720	NULL
LIN	NULL
AND	NULL
LEONARD	NULL
J	NULL
>	NULL
UJ	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

O	NULL
100	NULL
8	NULL
2	NULL
8	NULL
.2	NULL
2	NULL
>	NULL
1	NULL
>	NULL
80	NULL
3	NULL
<	NULL
6	NULL
si	NULL
2	NULL
p	NULL
<	NULL
m	NULL
3	NULL
i-	NULL
60	NULL
O	NULL
4	NULL
<	NULL
o	NULL
s	NULL
©	NULL
$	NULL
.	NULL

>	NULL
o	NULL
to	NULL
]	NULL
I	NULL
p	NULL
é	NULL
40	NULL
s	NULL
1	NULL
@	NULL
C	NULL
CC	NULL
CC	NULL
©	NULL
o	NULL
2	NULL
20	NULL
PMA	NULL
:	NULL
|-	NULL
+2	NULL
``	NULL
F..	NULL
``	NULL
+	NULL
,	NULL
,	NULL
``	NULL
-+	NULL
,	NULL
-+	NULL
,	NULL
-t	NULL
,	NULL
z-	NULL
t	NULL
,	NULL
-~-t+	NULL
o	NULL
oman	NULL
-	NULL
poo	NULL
poo	NULL
e	NULL
o	NULL
gp	NULL
o	NULL
Gp	NULL
a	NULL
&	NULL
PMA	NULL
:	NULL
|-4+o-4+o-4+/o~	NULL
+	NULL
,	NULL
~-	NULL
+	NULL
Effector	NULL
Vector	NULL
p930	NULL
Vector	NULL
p930	NULL
-	NULL
p930	NULL
a	NULL
A	NULL
&	NULL
,	NULL
\\	NULL
<	NULL
o	NULL
L_	NULL
E	NULL
Cun	NULL
``	NULL
und	NULL
U	NULL
x9	NULL
“	NULL
gs	NULL
«	NULL
&	NULL
a_	NULL
_i	NULL
a	NULL
Co	NULL
<	NULL
§®	NULL
BLCAT2	NULL
«	NULL
&	NULL
$	NULL
TKB-170/-139	NULL
®	NULL
38	NULL
C	NULL
p	NULL
a	NULL
<	NULL
pTKB	NULL
(	NULL
F	NULL
‘	NULL
s	NULL
é	NULL
‘	NULL
®	NULL
(	NULL
<	NULL
9	NULL
®	NULL
Reporter	NULL
p__	NULL
9	NULL
j	NULL
P	NULL
JMXHB-548/+97	NULL
pTkB-170-1839	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Both	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
maximal	NULL
promoter	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
enhancer	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
pBLCAT2	NULL
and	NULL
pTKB-170/-139	NULL
constructs	NULL
(	NULL
WT	NULL
;	NULL
Sp1	NULL
mutant	NULL
[	NULL
Sp1-MJ	NULL
,	NULL
Egr-1	NULL
mutant	NULL
[	NULL
Egr-MJ	NULL
,	NULL
and	NULL
Sp1	NULL
plus	NULL
Egr-1	NULL
mutant	NULL
[	NULL
Sp1/Egr-M	NULL
]	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
promoter	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
JOCAT	NULL
and	NULL
JMXHB-548/+97	NULL
constructs	NULL
(	NULL
WT	NULL
;	NULL
Sp1	NULL
mutant	NULL
[	NULL
Sp1-MJ	NULL
,	NULL
Egr-1	NULL
mutant	NULL
[	NULL
Egr-M	NULL
]	NULL
,	NULL
and	NULL
Sp1	NULL
plus	NULL
Egr-1	NULL
mutant	NULL
[	NULL
Sp1/Egr-M	NULL
]	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
both	NULL
panels	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
either	NULL
not	NULL
treated	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
overnight	NULL
before	NULL
being	NULL
harvested	NULL
for	NULL
CAT	NULL
assays	NULL
.	NULL

Data	NULL
represent	NULL
the	NULL
means	NULL
+	NULL
standard	NULL
errors	NULL
derived	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
activities	NULL
of	NULL
pBLCAT2	NULL
(	NULL
A	NULL
)	NULL
and	NULL
JOCAT	NULL
(	NULL
B	NULL
)	NULL
without	NULL
PMA	NULL
treatment	NULL
are	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
1.0	NULL
;	NULL
the	NULL
activities	NULL
of	NULL
other	NULL
constructs	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
fold	NULL
increases	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Cotransfections	NULL
of	NULL
HeLaS3	NULL
cells	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
following	NULL
combinations	NULL
:	NULL
pBLCAT2	NULL
plus	NULL
either	NULL
peDNA3.1neo	NULL
(	NULL
Vector	NULL
)	NULL
or	NULL
p930	NULL
,	NULL
wild-type	NULL
pTKB-170/-139	NULL
(	NULL
WT	NULL
)	NULL
plus	NULL
either	NULL
peDNA3.1neo	NULL
(	NULL
Vector	NULL
)	NULL
or	NULL
p930	NULL
,	NULL
and	NULL
pTKB-170/-139	NULL
construct	NULL
mutated	NULL
at	NULL
both	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
sites	NULL
(	NULL
Sp1/Egr-M	NULL
)	NULL
plus	NULL
p930	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
either	NULL
not	NULL
treated	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
overnight	NULL
before	NULL
harvest	NULL
and	NULL
measurement	NULL
of	NULL
CAT	NULL
activities	NULL
.	NULL

Data	NULL
represent	NULL
the	NULL
means	NULL
+	NULL
standard	NULL
errors	NULL
derived	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
pBLCAT2	NULL
plus	NULL
pcDNA3.1neo	NULL
without	NULL
PMA	NULL
treatment	NULL
is	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
1.0.	NULL
is	NULL
controlled	NULL
by	NULL
Spl	NULL
family	NULL
proteins	NULL
and	NULL
the	NULL
immediate-early	NULL
gene	NULL
product	NULL
Egr-1	NULL
.	NULL

Sp1	NULL
was	NULL
originally	NULL
identified	NULL
as	NULL
a	NULL
ubiquitously	NULL
expressed	NULL
mammalian	NULL
transcription	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
GC	NULL
box	NULL
promoter	NULL
elements	NULL
and	NULL
activates	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
(	NULL
13	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
important	NULL
for	NULL
the	NULL
promoter	NULL
activity	NULL
of	NULL
many	NULL
other	NULL
viral	NULL
and	NULL
cellular	NULL
genes	NULL
.	NULL

At	NULL
least	NULL
in	NULL
some	NULL
cases	NULL
,	NULL
Sp1	NULL
activates	NULL
transcription	NULL
by	NULL
cooperative	NULL
interaction	NULL
either	NULL
with	NULL
itself	NULL
(	NULL
41	NULL
)	NULL
or	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
the	NULL
EZ	NULL
protein	NULL
bound	NULL
to	NULL
the	NULL
bovine	NULL
papillo-mavirus	NULL
enhancer	NULL
(	NULL
29	NULL
)	NULL
,	NULL
Tat	NULL
protein	NULL
bound	NULL
to	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
,	NULL
NF-kBp65	NULL
bound	NULL
to	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
34	NULL
)	NULL
,	NULL
and	NULL
Rb	NULL
protein	NULL
bound	NULL
to	NULL
the	NULL
retinoblastoma	NULL
control	NULL
element	NULL
in	NULL
c-fos	NULL
,	NULL
c-myc	NULL
,	NULL
and	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
genes	NULL
(	NULL
49	NULL
)	NULL
.	NULL

In	NULL
the	NULL
IL-2RB	NULL
promoter	NULL
,	NULL
a	NULL
functional	NULL
Sp1	NULL
binding	NULL
site	NULL
located	NULL
at	NULL
the	NULL
-169	NULL
to	NULL
-155	NULL
region	NULL
is	NULL
required	NULL
mainly	NULL
for	NULL
basal	NULL
promoter	NULL
activity	NULL
.	NULL

Interestingly	NULL
,	NULL
Spl	NULL
is	NULL
also	NULL
physically	NULL
associated	NULL
with	NULL
Egr-1	NULL
in	NULL
vivo	NULL
upon	NULL
PMA	NULL
stimulation	NULL
.	NULL

Because	NULL
both	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
can	NULL
simultaneously	NULL
bind	NULL
to	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
Sp1-Egr-1	NULL
complex	NULL
formation	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
regulating	NULL
IL-Z2RB	NULL
promoter	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
either	NULL
Sp1	NULL
or	NULL
Egr-1	NULL
can	NULL
bind	NULL
to	NULL
an	NULL
Sp	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
IL-2RB	NULL
promoter	NULL
region	NULL
is	NULL
similar	NULL
to	NULL
a	NULL
report	NULL
(	NULL
39	NULL
)	NULL
that	NULL
the	NULL
ZIP	NULL
(	NULL
zinc	NULL
finger	NULL
protein	NULL
binding	NULL
)	NULL
region	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
binds	NULL
independently	NULL
to	NULL
either	NULL
Spl	NULL
or	NULL
Egr-1	NULL
proteins	NULL
.	NULL

However	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
Sp	NULL
binding	NULL
site	NULL
,	NULL
the	NULL
IL-2RB	NULL
promoter	NULL
has	NULL
an	NULL
adjacent	NULL
Egr-1	NULL
binding	NULL
site	NULL
just	NULL
downstream	NULL
of	NULL
the	NULL
Sp	NULL
site	NULL
at	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
,	NULL
which	NULL
only	NULL
binds	NULL
to	NULL
Egr-1	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
the	NULL
Sp	NULL
or	NULL
Egr-1	NULL
site	NULL
alone	NULL
at	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
diminished	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
,	NULL
whereas	NULL
simultaneous	NULL
mutation	NULL
of	NULL
both	NULL
sites	NULL
abolished	NULL
promoter	NULL
activity	NULL
.	NULL

Given	NULL
that	NULL
we	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
EBS	NULL
in	NULL
the	NULL
-56	NULL
to	NULL
-34	NULL
region	NULL
is	NULL
essential	NULL
but	NULL
not	NULL
sufficient	NULL
for	NULL
promoter	NULL
activity	NULL
(	NULL
30	NULL
)	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
both	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
and	NULL
the	NULL
EBS	NULL
at	NULL
-56	NULL
and	NULL
-34	NULL
are	NULL
required	NULL
,	NULL
but	NULL
neither	NULL
of	NULL
them	NULL
alone	NULL
is	NULL
sufficient	NULL
for	NULL
IL-2RB	NULL
promoter	NULL
activity	NULL
.	NULL

Thus	NULL
,	NULL
inducible	NULL
expression	NULL
of	NULL
the	NULL
IL-2RB	NULL
promoter	NULL
is	NULL
most	NULL
likely	NULL
regulated	NULL
by	NULL
functional	NULL
cooperation	NULL
between	NULL
both	NULL
the	NULL
Sp1	NULL
and	NULL
Egr-1	NULL
sites	NULL
in	NULL
the	NULL
-170	NULL
to	NULL
-139	NULL
region	NULL
and	NULL
the	NULL
EBS	NULL
in	NULL
the	NULL
-56	NULL
to	NULL
-34	NULL
region	NULL
.	NULL

Although	NULL
only	NULL
a	NULL
few	NULL
genes	NULL
are	NULL
known	NULL
to	NULL
be	NULL
regulated	NULL
by	NULL
Egr-1	NULL
in	NULL
hematopoietic	NULL
cells	NULL
,	NULL
the	NULL
ability	NULL
to	NULL
induce	NULL
Egr-1	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
mitogens	NULL
or	NULL
differentiation	NULL
stimuli	NULL
is	NULL
well	NULL
correlated	NULL
with	NULL
proliferation	NULL
of	NULL
B	NULL
lymphocytes	NULL
or	NULL
differentiation	NULL
of	NULL
monocytes	NULL
.	NULL

In	NULL
mature	NULL
B	NULL
cells	NULL
,	NULL
anti-p	NULL
antibodies	NULL
induce	NULL
Egr-1	NULL
expression	NULL
and	NULL
promote	NULL
cell	NULL
proliferation	NULL
,	NULL
whereas	NULL
in	NULL
immature	NULL
B	NULL
cells	NULL
,	NULL
these	NULL
antibodies	NULL
do	NULL
not	NULL
induce	NULL
Egr-1	NULL
expression	NULL
,	NULL
inhibit	NULL
cell	NULL
proliferation	NULL
,	NULL
and	NULL
thereby	NULL
eventually	NULL
cause	NULL
cell	NULL
death	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
U937	NULL
and	NULL
HL-60	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
,	NULL
PMA	NULL
induces	NULL
Egr-1	NULL
expression	NULL
and	NULL
causes	NULL
monocytic	NULL
differentiation	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
,	NULL
whereas	NULL
dexamethasone	NULL
blocks	NULL
Egr-1	NULL
expression	NULL
and	NULL
inhibits	NULL
differentiation	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
Egr-1	NULL
antisense	NULL
oligonucleotides	NULL
can	NULL
prevent	NULL
macrophage	NULL
differentiation	NULL
induced	NULL
by	NULL
PMA	NULL
,	NULL
whereas	NULL
constitutive	NULL
expression	NULL
of	NULL
Egr-1	NULL
favors	NULL
macrophage	NULL
differentiation	NULL
in	NULL
HL-60	NULL
cells	NULL
but	NULL
prevents	NULL
granulocyte	NULL
differentiation	NULL
induced	NULL
by	NULL
dimethyl	NULL
]	NULL
sulfoxide	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Egr-1	NULL
in	NULL
fibroblasts	NULL
and	NULL
certain	NULL
hematopoietic	NULL
cells	NULL
has	NULL
been	NULL
more	NULL
extensively	NULL
studied	NULL
;	NULL
however	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
role	NULL
played	NULL
by	NULL
Egr-1	NULL
and/or	NULL
other	NULL
Egr	NULL
family	NULL
proteins	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
coordinate	NULL
regulation	NULL
of	NULL
both	NULL
the	NULL
IL-2	NULL
(	NULL
39	NULL
)	NULL
and	NULL
IL-2RB	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
Egr-1	NULL
and	NULL
Sp1	NULL
suggests	NULL
that	NULL
these	NULL
factors	NULL
may	NULL
coordinately	NULL
influence	NULL
expression	NULL
of	NULL
a	NULL
range	NULL
of	NULL
T-cell-specific	NULL
genes	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
optimal	NULL
targets	NULL
for	NULL
the	NULL
Egr-1	NULL
site	NULL
have	NULL
not	NULL
been	NULL
defined	NULL
by	NULL
a	NULL
DNA	NULL
binding	NULL
site	NULL
selection	NULL
assay	NULL
,	NULL
and	NULL
we	NULL
now	NULL
show	NULL
here	NULL
that	NULL
the	NULL
Egr-1	NULL
site	NULL
in	NULL
the	NULL
IL-Z2RB	NULL
promoter	NULL
binds	NULL
well	NULL
to	NULL
Egr-1	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
site	NULL
is	NULL
markedly	NULL
different	NULL
from	NULL
the	NULL
canonical	NULL
site	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
hypothesize	NULL
that	NULL
other	NULL
noncanonical	NULL
Egr	NULL
sites	NULL
will	NULL
be	NULL
identified	NULL
in	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
other	NULL
T-cell-specific	NULL
genes	NULL
that	NULL
play	NULL
a	NULL
role	NULL
in	NULL
regulating	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
mitogen	NULL
stimulation	NULL
.	NULL

Interestingly	NULL
,	NULL
PHA	NULL
does	NULL
not	NULL
induce	NULL
Egr-1	NULL
,	NULL
but	NULL
some	NULL
of	NULL
the	NULL
cytokines	NULL
produced	NULL
by	NULL
the	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
mitogen	NULL
or	NULL
antigen	NULL
stimula-	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
A	NULL
IP	NULL
Anti-Sp1_	NULL
_	NULL
None	NULL
myt	NULL
PMA	NULL
(	NULL
Hr	NULL
)	NULL
00.5218	NULL
00.5218	NULL
Blot	NULL
Egr-1-	NULL
»	NULL
wat	NULL
=-	NULL
J	NULL
Egr-1	NULL
#	NULL
m	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Sp	NULL
!	NULL

=	NULL
>	NULL
]	NULL
se	NULL
1	NULL
2	NULL
3	NULL
4	NULL
BIP	NULL
Anti-Sp1	NULL
EtdBr	NULL
(	NULL
ug/m	NULL
!	NULL
)	NULL

-	NULL
.	NULL

f.	NULL
@	NULL
$	NULL
PMA	NULL
E	NULL
*T	NULL
Blot	NULL
Egr-1-	NULL
»	NULL
|	NULL
®	NULL
Egr-1	NULL
*	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Sp1	NULL
=	NULL
>	NULL
=	NULL
%	NULL
as	NULL
as	NULL
as	NULL
j	NULL
Sp1	NULL
1	NULL
2	NULL
3	NULL
4	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Association	NULL
of	NULL
Egr-1	NULL
with	NULL
Sp1	NULL
in	NULL
Jurkat	NULL
cells	NULL
upon	NULL
PMA	NULL
stimulation	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
30	NULL
min	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
,	NULL
2	NULL
h	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
18	NULL
h	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
lysed	NULL
,	NULL
and	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
(	NULL
IP	NULL
)	NULL
with	NULL
anti-Sp1	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
,	NULL
aliquots	NULL
of	NULL
lysates	NULL
were	NULL
blotted	NULL
with	NULL
anti-Egr-1	NULL
as	NULL
controls	NULL
for	NULL
the	NULL
amount	NULL
of	NULL
Egr-1	NULL
induced	NULL
at	NULL
the	NULL
different	NULL
time	NULL
points	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Total	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
either	NULL
untreated	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
2	NULL
h	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
treated	NULL
with	NULL
25	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
100	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
ug	NULL
of	NULL
ethidium	NULL
bromide	NULL
(	NULL
EtdBr	NULL
)	NULL
per	NULL
ml	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Western	NULL
blotting	NULL
was	NULL
performed	NULL
with	NULL
antisera	NULL
specific	NULL
for	NULL
Egr-1	NULL
or	NULL
Sp1	NULL
and	NULL
developed	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
.	NULL

Egr-1	NULL
and	NULL
Sp1	NULL
proteins	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
,	NULL
and	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
is	NULL
indicated	NULL
by	NULL
asterisks	NULL
.	NULL

tion	NULL
,	NULL
like	NULL
IL-1	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
induce	NULL
Egr-1	NULL
expression	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
Egr-1	NULL
is	NULL
induced	NULL
by	NULL
IL-1	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
during	NULL
T-cell	NULL
activation	NULL
and	NULL
serves	NULL
as	NULL
an	NULL
important	NULL
mediator	NULL
that	NULL
regulates	NULL
expression	NULL
of	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
genes	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
A.	NULL
Weiss	NULL
for	NULL
Jurkat	NULL
E6.1	NULL
cells	NULL
,	NULL
I.	NULL
Miyashi	NULL
for	NULL
MT	NULL
-2	NULL
cells	NULL
,	NULL
and	NULL
V.	NULL
Sukhatme	NULL
for	NULL
anti-Egr-1	NULL
antiserum	NULL
and	NULL
the	NULL
expression	NULL
vector	NULL
containing	NULL
Egr-1	NULL
cDNA	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
S.	NULL
John	NULL
,	NULL
E.	NULL
Soldaini	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
for	NULL
valuable	NULL
discussions	NULL
and	NULL
critical	NULL
comments	NULL
on	NULL
the	NULL
manuscript	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
for	NULL
suggesting	NULL
that	NULL
Egr-1	NULL
might	NULL
be	NULL
the	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
-158	NULL
to	NULL
-142	NULL
site	NULL
.	NULL

J.-X.L	NULL
.	NULL

was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
postdoctoral	NULL
fellowship	NULL
from	NULL
the	NULL
Arthritis	NULL
Foundation	NULL
,	NULL
Atlanta	NULL
,	NULL
Ga.	NULL
REFERENCES	NULL
1	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
inducible	NULL
transcription	NULL
activator	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
regulation	NULL
by	NULL
distinct	NULL
protein	NULL
subunits	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072:63-80	NULL
.	NULL

2	NULL
.	NULL

Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
1987	NULL
.	NULL

Methylation	NULL
interference	NULL
assay	NULL
for	NULL
analysis	NULL
of	NULL
DNA-protein	NULL
interactions	NULL
,	NULL
p.	NULL
12.2.1-12.2.4	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Strubl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
,	NULL
vol	NULL
.	NULL

2	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
3	NULL
.	NULL

Bamford	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

Grant	NULL
,	NULL
J.	NULL
D.	NULL
Burton	NULL
,	NULL
C.	NULL
Peters	NULL
,	NULL
G.	NULL
Kurys	NULL
,	NULL
C.	NULL
K.	NULL
Goldman	NULL
,	NULL
J.	NULL
Brennan	NULL
,	NULL
E.	NULL
Roessler	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Waldmann	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
2	NULL
receptor	NULL
B	NULL
chain	NULL
is	NULL
shared	NULL
by	NULL
IL-2	NULL
and	NULL
a	NULL
cytokine	NULL
,	NULL
provisionally	NULL
designated	NULL
IL-T	NULL
,	NULL
that	NULL
stimulates	NULL
T-cell	NULL
proliferation	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
lymphokine-activated	NULL
killer	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:4940-4944	NULL
.	NULL

4	NULL
.	NULL

Begley	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
J.	NULL
D.	NULL
Burton	NULL
,	NULL
M.	NULL
Tsudo	NULL
,	NULL
B.	NULL
H.	NULL
Brownstein	NULL
,	NULL
J.	NULL
L.	NULL
J.	NULL
Ambrus	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Waldmann	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
B	NULL
lymphocytes	NULL
express	NULL
the	NULL
p75	NULL
component	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
.	NULL

Leuk	NULL
.	NULL

Res	NULL
.	NULL

14:263-271	NULL
.	NULL

5	NULL
.	NULL

Cao	NULL
,	NULL
X.	NULL
M.	NULL
,	NULL
R.	NULL
A.	NULL
Koski	NULL
,	NULL
A.	NULL
Gashler	NULL
,	NULL
M.	NULL
McKiernan	NULL
,	NULL
C.	NULL
F.	NULL
Morris	NULL
,	NULL
R.	NULL
Gaffney	NULL
,	NULL
R.	NULL
V.	NULL
Hay	NULL
,	NULL
and	NULL
V.	NULL
P.	NULL
Sukhatme	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
and	NULL
character	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

REGULATION	NULL
OF	NULL
IL-ZRB	NULL
PROMOTER	NULL
BY	NULL
Egr-1	NULL
-	NULL
3721	NULL
ization	NULL
of	NULL
the	NULL
Egr-1	NULL
gene	NULL
product	NULL
,	NULL
a	NULL
DNA-binding	NULL
zinc	NULL
finger	NULL
protein	NULL
induced	NULL
by	NULL
differentiation	NULL
and	NULL
growth	NULL
signals	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:1931-1939.	NULL
.	NULL

Casey	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
A.	NULL
H.	NULL
Lichtman	NULL
,	NULL
and	NULL
M.	NULL
Boothby	NULL
.	NULL

1992	NULL
.	NULL

IL-4	NULL
induces	NULL
IL-2	NULL
receptor	NULL
p75	NULL
B-chain	NULL
gene	NULL
expression	NULL
and	NULL
IL-2-dependent	NULL
proliferation	NULL
in	NULL
mouse	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:3418-3426.	NULL
.	NULL

Cerdan	NULL
,	NULL
C.	NULL
,	NULL
Y.	NULL
Martin	NULL
,	NULL
M.	NULL
Courcoul	NULL
,	NULL
C.	NULL
Mawas	NULL
,	NULL
F.	NULL
Birg	NULL
,	NULL
and	NULL
D.	NULL
Olive	NULL
.	NULL

1995	NULL
.	NULL

CD28	NULL
costimulation	NULL
up-regulates	NULL
long-term	NULL
IL-2R	NULL
B	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
through	NULL
combined	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
regulation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:1007-1013.	NULL
.	NULL

Christy	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
D.	NULL
Nathans	NULL
.	NULL

1989	NULL
.	NULL

Functional	NULL
serum	NULL
response	NULL
elements	NULL
upstream	NULL
of	NULL
the	NULL
growth	NULL
factor-inducible	NULL
gene	NULL
zif268	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:4889-4895.	NULL
.	NULL

Christy	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
L.	NULL
F.	NULL
Lau	NULL
,	NULL
and	NULL
D.	NULL
Nathans	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
gene	NULL
activated	NULL
in	NULL
mouse	NULL
3T3	NULL
cells	NULL
by	NULL
serum	NULL
growth	NULL
factors	NULL
encodes	NULL
a	NULL
protein	NULL
with	NULL
``	NULL
zinc	NULL
finger	NULL
``	NULL
sequences	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:7857-7861	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Clipstone	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transmission	NULL
between	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
nucleus	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:1045-1083	NULL
.	NULL

Djeu	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
J.	NULL
H.	NULL
Liu	NULL
,	NULL
S.	NULL
Wei	NULL
,	NULL
H.	NULL
Rui	NULL
,	NULL
C.	NULL
A.	NULL
Pearson	NULL
,	NULL
W.	NULL
J.	NULL
Leonard	NULL
,	NULL
and	NULL
D.	NULL
K.	NULL
Blanchard	NULL
.	NULL

1993	NULL
.	NULL

Function	NULL
associated	NULL
with	NULL
IL-2	NULL
receptor-B	NULL
on	NULL
human	NULL
neu-trophils	NULL
.	NULL

Mechanism	NULL
of	NULL
activation	NULL
of	NULL
antifungal	NULL
activity	NULL
against	NULL
Candida	NULL
albicans	NULL
by	NULL
IL-2	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

150:960-970	NULL
.	NULL

Dukovich	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Wano	NULL
,	NULL
L.	NULL
thi	NULL
Bich	NULL
Thuy	NULL
,	NULL
P.	NULL
Katz	NULL
,	NULL
B.	NULL
R.	NULL
Cullen	NULL
,	NULL
J.	NULL
H.	NULL
Kebrl	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
second	NULL
human	NULL
interleukin-2	NULL
binding	NULL
protein	NULL
that	NULL
may	NULL
be	NULL
a	NULL
component	NULL
of	NULL
high-affinity	NULL
interleukin-2	NULL
receptors	NULL
.	NULL

Nature	NULL
327	NULL
:	NULL
518-522	NULL
.	NULL

Dynan	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1983	NULL
.	NULL

Isolation	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
discriminate	NULL
between	NULL
different	NULL
promoters	NULL
recognized	NULL
by	NULL
RNA	NULL
polymerase	NULL
IL	NULL
Cell	NULL
32:669-680	NULL
.	NULL

Espinoza-Delgado	NULL
,	NULL
I.	NULL
,	NULL
J.	NULL
R.	NULL
Ortaldo	NULL
,	NULL
R.	NULL
Winkler-Pickett	NULL
,	NULL
K.	NULL
Sugamura	NULL
,	NULL
L.	NULL
Varesio	NULL
,	NULL
and	NULL
D.	NULL
L.	NULL
Longo	NULL
.	NULL

1990	NULL
.	NULL

Expression	NULL
and	NULL
role	NULL
of	NULL
p75	NULL
interleukin	NULL
2	NULL
receptor	NULL
on	NULL
human	NULL
monocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171:1821-1826	NULL
.	NULL

Gashler	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
V.	NULL
P.	NULL
Sukhatme	NULL
.	NULL

1995	NULL
.	NULL

Early	NULL
growth	NULL
response	NULL
protein	NULL
1	NULL
(	NULL
Egr-1	NULL
)	NULL
:	NULL
prototype	NULL
of	NULL
a	NULL
zinc-finger	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Prog	NULL
.	NULL

Nucleic	NULL
Acid	NULL
Res	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

50:191-224	NULL
.	NULL

Gashler	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
S.	NULL
Swaminathan	NULL
,	NULL
and	NULL
V.	NULL
P.	NULL
Sukhatme	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
novel	NULL
repression	NULL
module	NULL
,	NULL
an	NULL
extensive	NULL
activation	NULL
domain	NULL
,	NULL
and	NULL
a	NULL
bipartite	NULL
nuclear	NULL
localization	NULL
signal	NULL
defined	NULL
in	NULL
the	NULL
immediate-early	NULL
transcription	NULL
factor	NULL
Egr-1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:4556-4571	NULL
.	NULL

Giri	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
M.	NULL
Abdich	NULL
,	NULL
J.	NULL
Eisenman	NULL
,	NULL
K.	NULL
Shanebeck	NULL
,	NULL
K.	NULL
Grabstein	NULL
,	NULL
S.	NULL
Kumaki	NULL
,	NULL
A.	NULL
Namen	NULL
,	NULL
L.	NULL
S.	NULL
Park	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
and	NULL
D.	NULL
Anderson	NULL
.	NULL

1994	NULL
.	NULL

Utilization	NULL
of	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
by	NULL
the	NULL
novel	NULL
cytokine	NULL
IL-15	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:2822-2830	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

21044-1051	NULL
.	NULL

Hagen	NULL
,	NULL
G.	NULL
,	NULL
S.	NULL
Muller	NULL
,	NULL
M.	NULL
Beato	NULL
,	NULL
and	NULL
G.	NULL
Suske	NULL
.	NULL

1992	NULL
.	NULL

Cloning	NULL
by	NULL
recognition	NULL
site	NULL
screening	NULL
of	NULL
two	NULL
novel	NULL
GT	NULL
box	NULL
binding	NULL
proteins	NULL
:	NULL
a	NULL
family	NULL
of	NULL
Sp1	NULL
related	NULL
genes	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:5519-5525	NULL
.	NULL

Hatakeyama	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Tsudo	NULL
,	NULL
S.	NULL
Minamoto	NULL
,	NULL
T.	NULL
Kono	NULL
,	NULL
T.	NULL
Doi	NULL
,	NULL
T.	NULL
Miyata	NULL
,	NULL
M.	NULL
Miyasaka	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1989	NULL
.	NULL

Interleukin-2	NULL
receptor	NULL
B	NULL
chain	NULL
gene	NULL
:	NULL
generation	NULL
of	NULL
three	NULL
receptor	NULL
forms	NULL
by	NULL
cloned	NULL
human	NULL
«	NULL
and	NULL
B	NULL
chain	NULL
cDNAs	NULL
.	NULL

Science	NULL
244:551-556	NULL
.	NULL

Huang	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1993	NULL
.	NULL

Increased	NULL
spacing	NULL
between	NULL
Sp1	NULL
and	NULL
TATAA	NULL
renders	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
defective	NULL
:	NULL
implication	NULL
for	NULL
Tat	NULL
function	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:6937-6944	NULL
.	NULL

Jeang	NULL
,	NULL
K.-T.	NULL
,	NULL
R.	NULL
Chun	NULL
,	NULL
N.	NULL
H.	NULL
Lin	NULL
,	NULL
A.	NULL
Gatignol	NULL
,	NULL
C.	NULL
G.	NULL
Glabe	NULL
,	NULL
and	NULL
H.	NULL
Fan	NULL
.	NULL

1993	NULL
.	NULL

In	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
binding	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
and	NULL
Sp1	NULL
transcription	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:6224-6233	NULL
.	NULL

Kbharbanda	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Nakamura	NULL
,	NULL
R.	NULL
Stone	NULL
,	NULL
R.	NULL
Hass	NULL
,	NULL
S.	NULL
Bernstein	NULL
,	NULL
R.	NULL
Datta	NULL
,	NULL
V.	NULL
P.	NULL
Sukhatme	NULL
,	NULL
and	NULL
D.	NULL
Kufe	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
early	NULL
growth	NULL
response	NULL
1	NULL
and	NULL
2	NULL
zinc	NULL
finger	NULL
genes	NULL
during	NULL
induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88:571-577	NULL
.	NULL

Kbharbanda	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Rubin	NULL
,	NULL
R.	NULL
Datta	NULL
,	NULL
R.	NULL
Hass	NULL
,	NULL
V.	NULL
Sukbatme	NULL
,	NULL
and	NULL
D.	NULL
Kufe	NULL
.	NULL

1993	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
early	NULL
growth	NULL
response	NULL
1	NULL
gene	NULL
in	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
by	NULL
okadaic	NULL
acid	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

4:17-23	NULL
.	NULL

Kingsley	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
A.	NULL
Winoto	NULL
.	NULL

1992	NULL
.	NULL

Cloning	NULL
of	NULL
GT	NULL
box-binding	NULL
proteins	NULL
:	NULL
a	NULL
novel	NULL
Sp1	NULL
multigene	NULL
family	NULL
regulating	NULL
T-cell	NULL
receptor	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4251-4261	NULL
.	NULL

Lai	NULL
,	NULL
J.-S.	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1992	NULL
.	NULL

Ethidium	NULL
bromide	NULL
provides	NULL
a	NULL
simple	NULL
tool	NULL
for	NULL
identifying	NULL
genuine	NULL
DNA-independent	NULL
protein	NULL
associations	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:6958-6992	NULL
.	NULL

Lau	NULL
,	NULL
L.	NULL
F.	NULL
,	NULL
and	NULL
D.	NULL
Nathans	NULL
.	NULL

1987	NULL
.	NULL

Expression	NULL
of	NULL
a	NULL
set	NULL
of	NULL
growth-related	NULL
immediate	NULL
carly	NULL
genes	NULL
in	NULL
BALB/c	NULL
3T3	NULL
cells	NULL
:	NULL
coordinate	NULL
regulation	NULL
with	NULL
c-fos	NULL
or	NULL
c-myc	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:1182-1186	NULL
.	NULL

Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
defective	NULL
gene	NULL
in	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
encodes	NULL
a	NULL
shared	NULL
interleukin	NULL
receptor	NULL
subunit	NULL
:	NULL
implications	NULL
for	NULL
cytokine	NULL
pleiotropy	NULL
and	NULL
redundancy	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

6:631-635	NULL
.	NULL

Li	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
D.	NULL
Knight	NULL
,	NULL
S.	NULL
P.	NULL
Jackson	NULL
,	NULL
R.	NULL
Tjian	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Botchan	NULL
.	NULL

1991	NULL
.	NULL

Direct	NULL
interaction	NULL
between	NULL
Sp1	NULL
and	NULL
the	NULL
BPV	NULL
enhancer	NULL
E2	NULL
protein	NULL
mediates	NULL
synergistic	NULL
activation	NULL
of	NULL
transcription	NULL
.	NULL

Cell	NULL
65:493-505	NULL
.	NULL

Lin	NULL
,	NULL
J.~X	NULL
.	NULL

,	NULL
N.	NULL
K.	NULL
Bhat	NULL
,	NULL
S.	NULL
John	NULL
,	NULL
W.	NULL
S.	NULL
Queale	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1993	NULL
.	NULL

3722	NULL
31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

LIN	NULL
AND	NULL
LEONARD	NULL
Characterization	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
receptor	NULL
B-chain	NULL
gene	NULL
pro-moter	NULL
:	NULL
regulation	NULL
of	NULL
promoter	NULL
activity	NULL
by	NULL
ets	NULL
gene	NULL
products	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:6201-6210	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Goodbourn	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Fischer	NULL
.	NULL

1987	NULL
.	NULL

Regulation	NULL
of	NULL
inducible	NULL
and	NULL
tissue-specific	NULL
gene	NULL
expression	NULL
.	NULL

Science	NULL
236:1237-1245	NULL
.	NULL

Munoz	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
the	NULL
Tax	NULL
protein	NULL
of	NULL
HTLV-1	NULL
.	NULL

Immunobiology	NULL
193:128-136	NULL
.	NULL

Nguyen	NULL
,	NULL
H.	NULL
Q.	NULL
,	NULL
B.	NULL
Hoffman-Liebermann	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Liebermann	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
zinc	NULL
finger	NULL
transcription	NULL
factor	NULL
Egr-1	NULL
is	NULL
essential	NULL
for	NULL
and	NULL
restricts	NULL
differentiation	NULL
along	NULL
the	NULL
macrophage	NULL
lineage	NULL
.	NULL

Cell	NULL
72:197-209	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Agranoff	NULL
,	NULL
E.	NULL
Pascal	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
interaction	NULL
between	NULL
the	NULL
DNA-binding	NULL
domains	NULL
of	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
and	NULL
Spl	NULL
mediates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
gene	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:6570-6583	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

1994	NULL
.	NULL

NF-ATp	NULL
:	NULL
a	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
the	NULL
co-ordinate	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
15:274-281	NULL
.	NULL

Seyfert	NULL
,	NULL
V.	NULL
L.	NULL
,	NULL
V.	NULL
P.	NULL
Sukhatme	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
Monroe	NULL
.	NULL

1989	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
a	NULL
zinc	NULL
finger-encoding	NULL
gene	NULL
in	NULL
response	NULL
to	NULL
positive	NULL
versus	NULL
negative	NULL
signaling	NULL
through	NULL
receptor	NULL
immunoglobulin	NULL
in	NULL
murine	NULL
B	NULL
lymphocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

92083-2088	NULL
.	NULL

Sharon	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
R.	NULL
Gnarra	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
100-kilodalton	NULL
protein	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
murine	NULL
interleukin	NULL
2	NULL
receptor	NULL
:	NULL
biochemical	NULL
evidence	NULL
that	NULL
p100	NULL
is	NULL
distinct	NULL
from	NULL
the	NULL
a	NULL
and	NULL
B	NULL
chains	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:4869-4873	NULL
.	NULL

Siegel	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
M.	NULL
Sharon	NULL
,	NULL
P.	NULL
L.	NULL
Smith	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
IL-2	NULL
receptor	NULL
B	NULL
chain	NULL
(	NULL
p70	NULL
)	NULL
:	NULL
role	NULL
in	NULL
mediating	NULL
signals	NULL
for	NULL
LAK	NULL
,	NULL
NK	NULL
,	NULL
and	NULL
prolif-crative	NULL
activities	NULL
.	NULL

Science	NULL
238:75-78	NULL
.	NULL

Skerka	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
L.	NULL
Decker	NULL
,	NULL
and	NULL
P.	NULL
F.	NULL
Zipfel	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
regulatory	NULL
clement	NULL
in	NULL
the	NULL
human	NULL
interleukin	NULL
2	NULL
gene	NULL
promoter	NULL
is	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
zinc	NULL
finger	NULL
proteins	NULL
Sp1	NULL
and	NULL
EGR-1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:22500-22506	NULL
.	NULL

Starkey	NULL
,	NULL
P.	NULL
M.	NULL
1991	NULL
.	NULL

Expression	NULL
on	NULL
cells	NULL
of	NULL
early	NULL
human	NULL
pregnancy	NULL
decidua	NULL
,	NULL
of	NULL
the	NULL
p75	NULL
,	NULL
IL-2	NULL
and	NULL
p145	NULL
,	NULL
IL-4	NULL
receptor	NULL
proteins	NULL
.	NULL

Immunology	NULL
73:64-70	NULL
.	NULL

Su	NULL
,	NULL
W.	NULL
,	NULL
S.	NULL
Jackson	NULL
,	NULL
R.	NULL
Tjian	NULL
,	NULL
and	NULL
H.	NULL
Echols	NULL
.	NULL

1991	NULL
.	NULL

DNA	NULL
looping	NULL
between	NULL
sites	NULL
for	NULL
transcriptional	NULL
activation	NULL
:	NULL
self-association	NULL
of	NULL
DNA-bound	NULL
Sp1	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:820-826	NULL
.	NULL

Sugamura	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Asao	NULL
,	NULL
M.	NULL
Kondo	NULL
,	NULL
N.	NULL
Tanaka	NULL
,	NULL
N.	NULL
Ishii	NULL
,	NULL
K.	NULL
Ohbo	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
and	NULL
T.	NULL
Takeshita	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
interleukin-2	NULL
receptor	NULL
y	NULL
chain	NULL
:	NULL
its	NULL
43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

role	NULL
in	NULL
the	NULL
multiple	NULL
cytokine	NULL
receptor	NULL
complexes	NULL
and	NULL
T	NULL
cell	NULL
development	NULL
in	NULL
XSCID	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14:179-205	NULL
.	NULL

Sukhatme	NULL
,	NULL
V.	NULL
P.	NULL
,	NULL
S.	NULL
Kartha	NULL
,	NULL
F.	NULL
G.	NULL
Toback	NULL
,	NULL
R.	NULL
Taub	NULL
,	NULL
R.	NULL
G.	NULL
Hoover	NULL
,	NULL
and	NULL
C.	NULL
H.	NULL
Tsai-Morris	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
novel	NULL
carly	NULL
growth	NULL
response	NULL
gene	NULL
rapidly	NULL
induced	NULL
by	NULL
fibroblast	NULL
,	NULL
epithelial	NULL
cell	NULL
and	NULL
lymphocyte	NULL
mitogens	NULL
.	NULL

Oncogene	NULL
Res	NULL
.	NULL

1:343-355	NULL
.	NULL

Sukhatme	NULL
,	NULL
V.	NULL
P.	NULL
,	NULL
X.	NULL
M.	NULL
Cao	NULL
,	NULL
L.	NULL
C.	NULL
Chang	NULL
,	NULL
C.	NULL
H.	NULL
Tsai-Morris	NULL
,	NULL
D.	NULL
Stamenk-ovich	NULL
,	NULL
P.	NULL
C.	NULL
Ferreira	NULL
,	NULL
D.	NULL
R.	NULL
Cohen	NULL
,	NULL
S.	NULL
A.	NULL
Edwards	NULL
,	NULL
T.	NULL
B	NULL
.	NULL

Shows	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
M.	NULL
Le	NULL
Beau	NULL
,	NULL
and	NULL
E.	NULL
Adamson	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
zinc	NULL
finger-encoding	NULL
gene	NULL
coregulated	NULL
with	NULL
c-fos	NULL
during	NULL
growth	NULL
and	NULL
differentiation	NULL
,	NULL
and	NULL
after	NULL
cellular	NULL
depolariza-tion	NULL
.	NULL

Cell	NULL
53:37-43	NULL
.	NULL

Suzuki	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
M.	NULL
Kundig	NULL
,	NULL
C.	NULL
Furlonger	NULL
,	NULL
A.	NULL
Wakeham	NULL
,	NULL
E.	NULL
Timms	NULL
,	NULL
T.	NULL
Mat-suyama	NULL
,	NULL
R.	NULL
Schmits	NULL
,	NULL
J.	NULL
J.	NULL
Simard	NULL
,	NULL
P.	NULL
S.	NULL
Ohashi	NULL
,	NULL
H.	NULL
Griesser	NULL
,	NULL
T.	NULL
Taniguchi	NULL
,	NULL
C.	NULL
J.	NULL
Paige	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Mak	NULL
.	NULL

1995	NULL
.	NULL

Deregulated	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
auto-immunity	NULL
in	NULL
mice	NULL
lacking	NULL
interleukin-2	NULL
receptor	NULL
B	NULL
.	NULL

Science	NULL
268:1472-1476	NULL
.	NULL

Tanaka	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
Takeuchi	NULL
,	NULL
T.	NULL
Shiobara	NULL
,	NULL
F.	NULL
Kitamura	NULL
,	NULL
Y.	NULL
Nagasaka	NULL
,	NULL
K.	NULL
Hamamura	NULL
,	NULL
H.	NULL
Yagita	NULL
,	NULL
and	NULL
M.	NULL
Miyasaka	NULL
.	NULL

1992	NULL
.	NULL

In	NULL
utero	NULL
treatment	NULL
with	NULL
monoclonal	NULL
antibody	NULL
to	NULL
IL-2	NULL
receptor	NULL
-chain	NULL
completely	NULL
abrogates	NULL
development	NULL
of	NULL
Thy-1+	NULL
dendritic	NULL
epidermal	NULL
cells	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

4487-491	NULL
.	NULL

Taniguchi	NULL
,	NULL
T.	NULL
1995	NULL
.	NULL

Cytokine	NULL
signaling	NULL
through	NULL
nonreceptor	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Science	NULL
268:251-255	NULL
.	NULL

Tjian	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1994	NULL
.	NULL

Transcriptional	NULL
activation	NULL
:	NULL
a	NULL
complex	NULL
puzzle	NULL
with	NULL
few	NULL
easy	NULL
pieces	NULL
.	NULL

Cell	NULL
77:5-8	NULL
.	NULL

Udvadia	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
K.	NULL
T.	NULL
Rogers	NULL
,	NULL
P.	NULL
D.	NULL
Higgins	NULL
,	NULL
Y.	NULL
Murata	NULL
,	NULL
K.	NULL
H.	NULL
Martin	NULL
,	NULL
P.	NULL
A.	NULL
Humphrey	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Horowitz	NULL
.	NULL

1993	NULL
.	NULL

Sp-1	NULL
binds	NULL
promoter	NULL
elements	NULL
regulated	NULL
by	NULL
the	NULL
RB	NULL
protein	NULL
and	NULL
Sp-1-mediated	NULL
transcription	NULL
is	NULL
stimulated	NULL
by	NULL
RB	NULL
coexpression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:3265-3269	NULL
.	NULL

Wei	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
K.	NULL
Blanchard	NULL
,	NULL
J.	NULL
H.	NULL
Liu	NULL
,	NULL
W.	NULL
J.	NULL
Leonard	NULL
,	NULL
and	NULL
J.	NULL
Y.	NULL
Djeu	NULL
.	NULL

1993	NULL
.	NULL

Activation	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
production	NULL
from	NULL
human	NULL
neutrophils	NULL
by	NULL
IL-2	NULL
via	NULL
IL-2-RfB	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

150:1979-1987	NULL
.	NULL

Yoshida	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Suzuki	NULL
,	NULL
J.	NULL
Fujisawa	NULL
,	NULL
and	NULL
H.	NULL
Hirai	NULL
.	NULL

1995	NULL
.	NULL

HTLV-1	NULL
oncopro-tein	NULL
tax	NULL
and	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

193:79-89	NULL
.	NULL

Zola	NULL
,	NULL
H.	NULL
,	NULL
H.	NULL
Weedon	NULL
,	NULL
G.	NULL
R.	NULL
Thompson	NULL
,	NULL
M.	NULL
C.	NULL
Fung	NULL
,	NULL
E.	NULL
Ingley	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Hapel	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
IL-2	NULL
receptor	NULL
p55	NULL
and	NULL
p75	NULL
chains	NULL
by	NULL
human	NULL
B	NULL
lymphocytes	NULL
:	NULL
effects	NULL
of	NULL
activation	NULL
and	NULL
differentiation	NULL
.	NULL

Immunology	NULL
72:167-173	NULL
.	NULL

